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Over the years there has been an increasing interest in the collection, storage and use of 
human biological samples for current and future research purposes (biomedical research). 
Human biological samples are defined as any component of the human body or human 
biological material. They are useful media for research into developing better means of 
preventing, diagnosing and treating human diseases. Growth in biomedical research has led to 
increased efforts in developing and revising laws, policies and regulations pertaining to the 
donation, use and storage of human biological samples. When making these laws, it is 
necessary to take into consideration the views and attitudes of the public as they are 
important in informing and guiding legislature which is in line with people’s views, beliefs 
and needs. This study sought to explore the views of 200 Pietermaritzburg out-patients 
currently being seen at Grey’s Hospital and Edendale Hospital. Data was obtained through a 
cross-sectional survey which was analysed quantitatively using SPSS. Results showed that 
over 50% of participants thought that consent was necessary for research on stored samples 
whether samples were identifiable or unidentifiable; and whether they were research derived, 
clinically derived or intended for research studying a disease other than what they were 
collected for. More than half of the participants thought that consent ought to be obtained 
when samples were initially collected and that it was the responsibility of the initial clinician 
or researcher to obtain consent for future research. An equal split was observed between 
participants who felt that one-time general consent was sufficient and those who thought it 
was necessary to impose limits to the use of their samples. Most participants wanted to be 
informed about clinically significant results and they wanted their doctors to be informed too. 
Participants regarded medical information as most sensitive and most likely to be misused. 
They regarded all types of medical information as important. 
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Chapter 1: Introduction 
 
1.1 Background 
There has been increasing interest in human biological samples that may be used for present, or 
stored for future research purposes (Kapp, 2006). Research on human biological samples has 
played an important role in providing a vast amount of information pertaining to diagnosing, 
treating, and preventing certain human diseases (Elger & Caplan, 2006). Three strategies have 
been identified for the collection of these samples and obtaining consent for their use (Gefenas et 
al., 2012). The first strategy is where human biological samples are specifically sought for 
current research purposes and participants provide their consent for these (Gefenas et al., 2012). 
The second strategy involves requesting patients undergoing medical procedures or current 
research participants to donate biological samples and consent for their use in future research that 
is not yet known (Gefenas et al., 2012; Kapp, 2006).  
 
The third strategy involves the utilisation of residual samples from medical procedures, and the 
storage of these for future research purposes (Elger & Caplan, 2006; Gefenas et al., 2012). These 
samples are typically collected from leftover biological samples obtained from medical visits, 
which were stored and used without the consent of the patients. This raised many ethical 
concerns (Elger & Caplan, 2006). Biomedical research involving human participants raises a 
variety of ethical concerns pertaining to values of dignity, bodily autonomy, autonomy, and 
privacy (Kapp, 2006). In recent years, biobanks have been established in order to enable willing 
donors to donate their biological materials; although this is a new alternative, ethical concerns 
still remain with regard to whether once-off consent is sufficient, and how consent should be 
given, and for the purposes of which research (Porter et al., 2000). 
 
1.2 Structure of report 
This study aims to investigate the attitudes of Pietermaritzburg government hospital out-patients 
to the collection and storage of human biological samples for future research purposes. The main 
areas of investigation will include attitudes to the use of their human biological samples for 
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research purposes, with a particular focus on: (1) how consent should be obtained for research on 
stored samples; (2) whether people would desire to receive results of clinical significance; (3) 
people’s perceptions of confidentiality, and (4) whether there are any significant differences 
based on participant demographics (race, gender, age). 
 
This thesis begins with the theoretical framework. This provides an overview of the history of 
research ethics which focuses on how past research atrocities on human participants have led to 
the conceptualisation of ethical codes and specific ethical requirements to avoid the mistakes of 
the past (Emanuel, Wendler, & Grady, 2000). It will then discuss the four philosophical 
principles guiding ethical research, which will be followed by a more practical application of 
these, namely the eight ethical requirements for research (Emanuel, Wendler, Killen, & Grady, 
2004). This will be followed by a literature review. Biomedical research will then be introduced, 
and the distinction will be made between samples collected for clinical purposes (then later used 
for research) and samples collected solely for research purposes.  
 
The ethical, legal and social considerations of research using stored human biological samples 
will be discussed, and arguments from different authors will be presented. Biomedical research 
in the African context will then be introduced and the ethical considerations of this will be 
discussed. This literature review will end by discussing public attitudes to the use of their human 
biological samples for research purposes 
 
The researcher will then discuss the aims and rationale of this study, followed by the 
methodologies used to carry out the aims of the study. Results of the study will then be 
presented, followed by a discussion which will incorporate the theoretical framework and the 






Chapter 2: Theoretical framework 
 
2.1 Research ethics 
An ethically sound research study is one that is scientifically valid and justifiable, and one which 
does good and avoids harm (Orb, Eisenhauer, & Wynaden, 2000). One of the main aims and 
functions of research ethics is to ensure that the welfare of research participants is protected 
throughout the research process (Wassenaar, 2006; Wassenaar & Mamotte, 2012). This research 
process with human participants involves various stages of the research, namely the planning, 
designing, implementing, and reporting of research (Wassenaar, 2006). In any research study, it 
is vital to protect the dignity and rights of human beings and efforts need to be made to reduce 
any potential harm that could be sustained by participants as a result of participation in a 
particular research study (Orb et al., 2000). Under no circumstances should participants be 
treated as a simple means to the researcher’s ends, and it is the obligation of the researcher to 
treat all participants ethically (Wassenaar, 2006). 
 
2.1.1 The history of research ethics 
In the past few decades, the main foundations of guidance for the ethical conduct of clinical 
research have been the Nuremberg Code, the Declaration of Helsinki, the Belmont Report, the 
International Ethical Guidelines for Biomedical Research Involving Human Subjects, and similar 
documents (Emanuel et al., 2000). Several of these ethical guidance documents were written in 
reaction to particular events that happened and were hence intended to serve as a means to avoid 
recurrence of earlier research mistakes (Emanuel et al., 2000). Hence, these guidelines often tend 
to incline towards more particular ethical considerations associated with particular events, while 
relegating other important ethical considerations (Emanuel et al., 2000). 
 
The Nuremburg Code, published in 1948, was written in response to the atrocities committed by 
the Nazi medical researchers in Germany during World War 2 (Emanuel et al., 2000; Wassenaar, 
2006; Wassenaar & Mamotte, 2012). Some experiments involving hypothermia were conducted 
on prisoners between 1942 and 1943 in the Dachau concentration camp and, while these 
 
 4 
experiments were disguised as medical research, they were brutal crimes (Berger, 1990). The 
Dachau human hypothermia study aimed at establishing the most effective treatment for victims 
of hypothermia (Berger, 1990). The study involved the immersion of prisoners into a tank of iced 
water, with some subjects dressed, others naked, and some anesthetised, while others were 
conscious (Berger, 1990). Most of the subjects’ participation in this study was coerced, with 
some participating ‘voluntarily’ in response to rarely fulfilled promises of release from the 
concentration camps (Berger, 1990).  
 
The Nuremberg Code was part of the judicial decision formed in response to the atrocities of the 
Nazi era (Emanuel et al., 2000) and various other brutal crimes against individuals disguised as 
research. It focused on the need for individual informed consent and a favourable risk/benefit 
ratio in research for participants; however, it failed to speak about fair subject selection or 
independent review (Emanuel et al., 2000; Wassenaar & Mamotte, 2012). 
 
After the Nuremberg Code, the Declaration of Helsinki was first developed in 1964 by the World 
Medical Association to remedy omissions that were believed to have been made in the 
Nuremberg Code (Emanuel et al., 2000). The Declaration of Helsinki focused on physicians 
conducting research with human participants, and particularly focused on favourable risk/benefit 
ratio and independent ethics review (Emanuel et al., 2000). It also emphasised the distinction 
between therapeutic and non-therapeutic research (Emanuel et al., 2000). 
 
The Belmont Report was written in 1979 by the National Commission for the Protection of 
Human Subjects of Biomedical and Behavioural Research as a response to research atrocities 
such as the Tuskegee Syphilis Study and other research abuses committed between 1932 and 
1972 (Emanuel et al., 2000; Isler, Odulana, & Corbie-Smith, 2011). Essentially, the Tuskegee 
Syphilis Study was used as a name to group all of the medical abuses and mistreatment of 




The Tuskegee Syphilis Study was an observational study comprised of over 400 African 
American share-croppers (men) with untreated syphilis (Corbie-Smith, 1999). It began in 1932 
and was conducted by the United States Public Health Service as they aimed to document the 
course of development of syphilis (in blacks), and whether there were any significant clinical 
differences in its manifestations (Corbie-Smith, 1999). The men were allegedly not informed that 
they had syphilis, nor were they counselled on how to avoid the spread of the disease (Corbie-
Smith, 1999). Treatment was not available when the study began, but when it became available, 
it was not given throughout the 40-year duration of the study (Corbie-Smith, 1999). This study 
was documented as the longest non-therapeutic experiment on humans in the history of 
medicine. By the end of the study, over 100 men had died from syphilis and other related 
illnesses (Corbie-Smith, 1999). The study finally came to an end in 1972 when ethical concerns 
about it were raised in the media (Corbie-Smith, 1999).  
 
In the aftermath of such atrocities, the Belmont Report concentrated on informed consent, 
favourable risk/benefit ratio, as well as ensuring the fact that when research risk is high, 
vulnerable populations are not targeted (Emanuel et al., 2000). At institutions receiving federal 
grants, this report required that institutional review boards (IRBs) be established and that these 
federally funded grants be subject to review by IRBs, to regulate whether the selection process 
was fair and that rights and welfare of the intended human participants of any research were 
acknowledged and protected (Corbie-Smith, 1999).  
 
Another outcome of the Tuskegee Syphilis Study was the emphasis placed on research being 
participant centred and community engaged (Isler et al., 2011). This meant that participants’ 
needs and interests should be central to research, unlike previously when the professional needs 
of the researcher were the focus (Isler et al., 2011). This shift of focus to participants’ needs and 
interests had the potential to influence a variety of factors within the context of research with 
human participants, including recruitment strategies, participation assignment to groups and the 






2.1.2 The four philosophical principles guiding ethical research 
Through the application of appropriate ethical principles, harm incurred by research participants 
can be prevented or at least reduced (Orb et al., 2000). There are four widely accepted 
philosophical principles, namely autonomy, beneficence, non-maleficence, and justice, and these 
four principles have been applied to research in various ways to determine whether or not 
research is ethical (Wassenaar, 2006; Wassenaar & Mamotte, 2012).  
 
Autonomy is seen as the participant’s right to be informed about the intended study, the right to 
freely decide whether they wish to participate, and the right to withdraw without penalty at any 
stage (Orb et al., 2000). Autonomy can be operationally expressed in the essential requirements 
for voluntariness, informed consent, and the protection of participants’ confidentiality throughout 
the research process (Wassenaar, 2006). 
 
The philosophical principle of beneficence states that researchers must take all possible measures 
to ensure that benefits are maximised and risks are minimised for research participants in the 
research study (Orb et al., 2000). This principle can be viewed in combination with the principle 
of non-maleficence (see below) and together they can be determinants of a favourable 
risk/benefit ratio (Wassenaar, 2006). A favourable risk/benefit ratio is determined by the 
weighing of possible risks/harms, that might be directly incurred by the participants, against the 
benefits that participants may gain as a result of participation, and ensuring that the benefits 
outweigh the risks (Wassenaar, 2006). It should be noted that monetary incentives given to 
research participants cannot be regarded as benefits, and benefits should be more direct (such as 
better access to health facilities, skills development, and so forth) (Wassenaar, 2006). 
 
Researchers also need to ensure that no direct or indirect harm is incurred by the participant as a 
result of participation (Orb et al., 2000; Wassenaar, 2006). This refers to the philosophical 
principle of non-maleficence and means that researchers need to take necessary steps and 
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precautions to minimise and avoid anticipated harms (Wassenaar, 2006). Wrongs also fall under 
this principle and, although participants may not be harmed by research, they may be wronged in 
some way and this should also be avoided (Wassenaar, 2006). 
 
 
The final philosophical principle guiding ethical research is that of justice and this requires that 
research participants be treated fairly throughout the duration of the research (Orb et al., 2000). 
This applies to all stages, including the initial stages of the research, where there should be a fair 
selection of participants, and to the course of the research where those who stand to benefit the 
most from a particular research, should consequently bear the most burdens (favourable 
risk/benefit ratio) (Orb et al., 2000; Wassenaar, 2006). 
 
2.1.3 Towards a more practical application of research ethics: The eight ethical 
requirements 
While there is no doubt that these four universally accepted philosophical principles are useful 
and important, their practical implications and applications as applied to research have been 
unclear (Emanuel et al., 2000; Emanuel, Wendler, Killen, & Grady, 2004; Wassenaar, 2006; 
Wassenaar & Mamotte, 2012). This is due to their abstract nature, and the difficulty in 
practically applying them to different people and in varied contexts (Wassenaar & Mamotte, 
2012). Emanuel et al. (2004) provided eight requirements which attempted to outline a 
systematic and coherent framework for evaluating clinical studies that incorporate all relevant 
ethical considerations. These eight requirements are: (1) collaborative partnership, (2) social and 
scientific value, (3) scientific validity, (4) fair participant selection, (5) favourable risk/benefit 
ratio, (6) independent ethical review, (7) informed consent, and (8) ongoing respect for 
participants and study community (Emanuel et al., 2004; Wassenaar, 2006).  
 
The eight ethical requirements for clinical research aim to minimise the possibility of 
exploitation mainly by ensuring that all human participants are treated with respect while they 
contribute to social good (Emanuel et al., 2000). The order in which the principles are listed 
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below is significant as it represents the chronological order from the conception of the research, 
to its formulation and its implementation, and they serve as the guideline to the ethical 
development, implementation, and review of individual clinical protocols (Emanuel et al., 2000). 
A brief description of each of the ethical requirements follows: 
 Collaborative partnership requires the development of equal partnerships with 
researchers, makers of health policies, and the target community (Emanuel et al., 2004). 
It involves partnership in sharing responsibilities for determining research as expressed 
by a community need, and assessing the value of research and its implementation 
(Emanuel et al., 2004). Communities should be involved in all research stages, from the 
planning of the study right through to the dissemination of the results (Wassenaar & 
Mamotte, 2012). Ensuring that researchers show respect for the community’s values, 
culture, traditions, and social practices is also an important aspect pertaining to this 
requirement (Emanuel et al., 2004; Wassenaar 2006). Lastly, the benefits of the research 
should be shared with the recruited participants and the host communities (Emanuel et 
al., 2004; Wassenaar, 2006). 
 Social/scientific value stresses the fact that research with human participants should 
pursue questions that are of value to society or particular communities in society 
(Wassenaar, 2006). Clinical research that imposes risk on human participants can only be 
justified if, firstly, it identifies who may benefit from the research directly or indirectly 
and, secondly, if society will gain knowledge or possible interventions that prove to be 
valuable (Emanuel et al., 2004; Wassenaar, 2006). This means that, in responding to the 
needs of the community, researchers need to include intervention studies, action research, 
or advocacy efforts in their research design (Nyambedha, 2008, in Wassenaar & 
Mamotte, 2012). Research that lacks social/scientific value is unethical as it wastes scarce 
resources that could be used for other beneficial studies, and because it imposes possible 
harm on participants without any social/scientific benefit (Emanuel et al., 2004). 
 Scientific validity Researchers need to ensure that the design, methodology, and data 
analysis of their study is adequate and best suited to answer their research question 
(Wassenaar, 2006). Inappropriate or flawed methodology is unethical as it yields 
 
 9 
inaccurate results, wastes scarce resources, and exploits participants without social 
benefits (Emanuel et al., 2000; Emanuel et al., 2004; Wassenaar, 2006). 
 Fair participant selection requires that the participants selected for any particular 
research be those to whom the scientific goals of the study apply (Wassenaar, 2006). The 
exclusion of certain groups or people should be justified by valid social/scientific reasons 
(Emanuel et al., 2000). Vulnerability, privilege, easy accessibility, or any other factors 
that are unrelated to the study should not be used as a basis for selecting participants 
(Emanuel et al., 2000). The requirement of fairness also holds that those who stand to 
benefit the most from a study should bear most of its burdens (Emanuel et al., 2000; 
Emanuel et al., 2004; Wassenaar, 2006). 
 Favourable risk/benefit ratio holds that researchers need to assess the potential 
risks/costs and benefits of the research to its participants and evaluate ways in which the 
risks/costs can be minimised in order to ensure a favourable risk/benefit ratio whereby 
the benefits outweigh the risks (Emanuel et al., 2000; Emanuel et al., 2004; Wassenaar, 
2006). Payment of research participants cannot be considered a fair benefit as it does not 
offset risks (Emanuel et al., 2000; Emanuel et al., 2004; Wassenaar, 2006). However, 
research participants may be reimbursed for costs (e.g. travel money) incurred by them 
(Emanuel et al., 2000; Emanuel et al., 2004; Wassenaar, 2006). While there may still be 
debate surrounding the payment of participants in South Africa, all South African ethical 
guidelines support reimbursement payments (Koen, Slack, Barsdorf & Essack, 2008) 
 Independent ethics review is important for issues pertaining to social accountability, and 
for minimising conflicts among researchers and research teams regarding methodology 
(Emanuel et al., 2000). Ethics review should involve an independent and competent 
research ethics committee (REC) reviewing a proposed study prior to commencement of 
data collection. The main goals of this committee are to ensure the protection of human 
participants and to enhance the quality of the proposed research (Emanuel et al., 2000; 
Emanuel et al., 2004; Wassenaar, 2006). 
 According to Wassenaar (2006), informed consent is made up of appropriate information, 
ensures participants’ competence and understanding, and provides for voluntariness in 
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participation and freedom to decline or withdraw from the study, even after the latter has 
started. Formalisation of consent, which is mainly done in writing, also forms part of 
informed consent to participation (Emanuel et al., 2000; Emanuel et al., 2004; 
Wassenaar, 2006). This ethical prerequisite demands that the researcher provides 
potential participants with comprehensive and truthful information with regard to the 
research and its methodology, as well as the potential risks and benefits that may directly 
or indirectly arise should they agree to participate in the research (Emanuel et al., 2000; 
Emanuel et al., 2004; Wassenaar, 2006). The main purpose of informed consent is to 
ensure the voluntary, uncoerced nature of participation, and it gives the participants the 
choice in participating in studies that are consistent with their values, interests and 
preferences (Emanuel et al., 2000). It respects the autonomy of individuals’ decisions. 
 Finally, ongoing respect for participants and study communities requires that researchers 
develop and implement procedures to protect the confidentiality of recruited and enrolled 
participants throughout the study (Emanuel et al., 2000; Emanuel et al., 2004; Wassenaar, 
2006). Risks and benefits pertaining to participation in a study should be reassessed over 
time, and any new developments need to be explained to participants (Wassenaar, 2006). 
It is also necessary for researchers to ensure that participants know they can withdraw at 
any stage of the research without any penalties (Emanuel et al., 2000; Emanuel et al., 
2004). It is also the responsibility of researchers to inform participants and the study 
community of the results of the research, in a language which they are able to understand, 
and in a format that is relevant and appropriate (Emanuel et al., 2000; Emanuel et al., 






Chapter 3: Literature Review 
 
3.1 Biomedical research: International context 
3.1.1 What is biomedical research? 
According to the Organisation for Economic Cooperation and Development (2007), biomedical 
research can be defined in three components. Biomedical research is: 
... the study of specific diseases and conditions (mental or physical), including detection, 
cause, prophylaxis, treatment, and rehabilitation of persons; the design of methods, drugs, 
and devices used to diagnose, support, and maintain the individual during and after 
treatment for specific diseases or conditions; and the scientific investigation required to 
understand the underlying life processes which affect disease and human well-being, 
including such areas as cellular and molecular bases of diseases, genetics. and 
immunology. (Organisation for Economic Cooperation and Development, 2007, p. 70). 
 
The main purpose of carrying out biomedical research is to facilitate the systematic collection 
and analysis of data from which ‘generalisable conclusions’ can be made (Kapp, 2006). This 
may consequently help in the improvement of future care of presently unknown beneficiaries 
(Kapp, 2006). Therefore, biomedical research relies on human participants as the primary source 
of data, and much of this data includes the use of human biological samples (Kapp, 2006; Porter 
et al., 2000). Although research on animals has proved beneficial, it sometimes provides only 
limited insight in relation to humans (Bathe & McGuire, 2009). Due to this limited insight, Bathe 
and McGuire (2009) also highlight the fact that it becomes difficult to ethically justify research 
on animals. 
 
3.1.2 Human biological samples 
Research with human biological samples has great scientific potential for combating severe 
illnesses like cardiovascular diseases, metabolic disorders, hormonal pathologies, cancer, 
diseases of the nervous system, infectious diseases, and diseases of the immune system (Simitis, 
2004). Research with human biological samples is not only beneficial to the public, but 




Human biological samples may be obtained in three different ways namely: (1) solely for 
specific research purposes, (2) for diagnostic or therapeutic procedures (clinical purposes) with 
no intention for them to be used in research, (3) or they may be sought for specific medical or 
research purposes with the intention of using them for future unspecified research purposes 
(Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of 
Canada, & Social Sciences and Humanities Research Council of Canada, 2010; Gefenas et al., 
2012; Kapp, 2006; National Bioethics Advisory Committee, 1999). When individuals contribute 
their human biological samples solely for research purposes, the researcher is required to inform 
them fully of the study (by means of an information sheet) before they provide their consent (by 
means of a separate consent form) (Canadian Institutes of Health Research et al., 2010). The 
consent form needs to provide research participants with the option to withdraw their samples 
from the study with no penalties, and should they withdraw, they may decide whether already 
obtained data from their samples may be used (Canadian Institutes of Health Research et al., 
2010). 
 
Human biological samples that are obtained from diagnostic or therapeutic procedures (clinical 
purposes) with no intention for them to be used in research, and samples that are obtained from 
specific medical or research purposes with the intention of using them for future unspecified 
research purposes, are referred to as residual human biological materials (Gefenas et al., 2012; 
Kapp, 2006; National Bioethics Advisory Committee, 1999). Residual human biological samples 
can also be obtained after death if the relatives of the deceased are willing to consent (Al-Jumah 
et al., 2011). 
 
These samples are referred to as residual because of their potential secondary use which may or 
may not have been apparent when the tissue was obtained (Canadian Institutes of Health 
Research et al., 2010). Previously, researchers kept these residual samples and they were used 
without informed consent, as research with them was associated with little or no risk (Porter et 
al., 2000). However, as a result of this, ethical questions began to emerge, such as  
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 Is it appropriate to use stored biological materials in ways originally not contemplated, 
either by the people from whom the materials came or by those who collected the 
materials: 
 Does such use harm anyone’s interest?  
 Does it matter whether the material is identified or identifiable as to its source, or linked 
or linkable to other medical or personal data regarding the source? (National Bioethics 
Advisory Committee, 1999) 
 
Gefenas et al. (2012) refer to three models of consent when using residual human biological 
materials, namely: the precautionary consent model, the presumed consent model, and the no 
consent model. The precautionary consent model refers to consent that is obtained for research 
use of residual materials in future unspecified research (Gefenas et al., 2012). This consent is 
usually sought from patients undergoing diagnostic or therapeutic procedures, or current research 
participants, and the material may be stored in the absence of any concrete future research plans, 
in order to avoid the need to re-contact individuals for consent (Gefenas et al., 2012).  
 
The presumed consent model, which is only applicable in some countries such as Belgium, and 
the Netherlands, refers to identifiable human biological samples collected during diagnostic or 
therapeutic procedures and stored without the individuals’ consent for future research use 
(Gefenas et al., 2012). These residual materials are then treated as already-existing research 
collections and this relies on the assumption that members of society are aware of the fact that 
such residual samples are routinely stored for biomedical research (Gefenas et al., 2012). In 
hospitals in these countries, individuals may be informed at hospital admission of the storage of 
samples, through posters or through brochures, and an opt-out option made available to them 
(Gefenas et al., 2012).  
 
The no consent model refers to not requiring consent for research use of identifiable human 
biological samples (Gefenas et al., 2012). For example, in the US Office for Human Research 
Protections at the Department of Health and Human Services, a guideline was issued which 
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disregarded research on anonymous residual materials as human research, thus making it exempt 
from ethics review and consent requirements (Gefenas et al., 2012). 
 
3.1.3 Types of human biological materials 
Human biological samples may be categorised in one of four categories according to the amount 
of information that is conveyed to the researcher about the person (Canadian Institutes of Health 
Research et al., 2010; National Bioethics Advisory Committee, 1999). Samples can be 
categorised as follows (Canadian Institutes of Health Research et al., 2010; National Bioethics 
Advisory Committee, 1999): 
 Identified human biological samples: These samples are labelled with the personal details 
of the individual, such as their name and their patient numbers. This enables researchers 
to make associations between the data obtained from the research and the specific 
individual. 
 Coded human biological samples: With these samples, personal and identifying details 
are replaced with codes. Accessibility to these codes is often kept by principal 
investigators (or similar authorities), in case it becomes necessary to re-link the sample 
and the identity of the individual. 
 Anonymised/unlinked human biological samples: Samples which have had all possible 
identifiers removed but these have not been replaced with any codes. This makes future 
re-identification and re-linkage extremely difficult. 
 Anonymous/unidentified human biological samples: These samples are ones which have 
never had any personal or identifying details attached to them. 
 
3.1.4 What are biobanks? 
The rapid growth and development of biotechnological research has led to the use of biobanks as 
a means managing biological samples (Kettis-Linblad, Ring, Viberth, & Hanson, 2005). The 
American Society of Human Genetics (ASHG) has defined DNA banking as a facility that stores 
DNA for future analysis (Godard, Schmidtke, Cassiman, & Ayme 2003). Simitis has defined 
biobanks as “collections of samples of human bodily substances that are, or can be, associated 
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with personal data and information on their donors” (Simitis, 2004, p. 21). Cells, tissues, blood, 
and DNA are examples of bodily samples and these contain genetic information about a person 
(Simitis, 2004). Similarly, the Biobank Ethics Committee of the University of Witwatersrand 
(Wits) Human Research Ethics Committee (HREC) (Medical) has defined biobanks as 
“repositories where organised collections of human biological materials (HMBs) and associated 
data from large numbers of individuals are collected, stored, and distributed for the purpose of 
health research” (2013, p. 1).  
 
The use of biobanks allows for identification of diseases, which is hoped to lead to personalised 
prevention programmes and treatments (Kettis-Linblad et al., 2005). Being able to identify 
relationships between genes, lifestyle, environmental factors and susceptibility to illness may 
serve as a useful therapeutic tool (Simitis, 2004). Biobanks also have the potential to contribute 
to the development of certain drugs tailored specifically to particular individual patients or 
specific diseases (Simitis, 2004). Biobanks can either be public or private, with public biobanks 
often referred to as population banks (Biobank Ethics Committee of the Wits HREC (Medical), 
2013). Human biological samples stored in population biobanks are used for the benefit of the 
health of the population (Biobank Ethics Committee of the Wits HREC (Medical), 2013). 
 
Biobanks are those facilities that are established and used solely for the purpose of research 
(Simitis, 2004). Facilities such as laboratories are not classified as biobanks because they merely 
record and store personal data from bodily samples (Simitis, 2004). Biobanks are seen as a vital 
resource for biomedical research, and more broadly, public health; therefore, their establishment 
can be seen as meeting the public interest (Kettis-Linblad et al., 2005). In order for biobanks to 
succeed, sample donors need to allow access to their personal data which touches private aspects 
of their life, without revealing their identity (Godard, 2003; Simitis, 2004). The efficiency and 
resourcefulness of these biobanks, therefore, is highly dependent on people’s willingness to 
contribute samples for both research and storage (Kettis-Linblad et al., 2005). Public support is 
thus seen as an essential component in securing the long-term viability and sustainability of 




3.2 Ethical considerations in biomedical research using human biological samples 
According to Porter et al. (2000), there are various legal, ethical, and social consequences of 
creating and storing human biological samples. Working around the issue of consent to use these 
samples comes with its own sets of difficulties (Porter et al., 2000). According to Gibbons and 
Kaye (2007), the considerable growth in research on stored biological samples and genetic 
research has led to the increasing need to devise a suitable and efficient framework that will help 
in the appropriate management of genetic databases, both nationally and internationally. These 
frameworks should not solely serve the purpose of safeguarding vital rights, principles, and 
values but should also seek to promote beneficial research for the good of the public and to 
preserve public confidence and support. This section will review the ethical considerations of 
biomedical research using the eight ethical requirements of research ethics as outlined in Section 
2.2.3 above. Since there is a great deal of overlap within these and biomedical research, only the 
following five will be discussed: independent review, social and scientific value, favourable 




3.2.1 Independent review 
According to Simitis (2004), it is important for regulatory provisions to be put in place in order 
to protect participants, their relatives, and their population groups from genetic discrimination 
and stigmatisation. These regulatory provisions need to ensure that all research respects the 
autonomy of participants, and that no unacceptable risks are incurred by participants, their 
relatives, or their population group (Simitis, 2004). The National Bioethics Advisory Committee 
(1999) states that institutional review boards (IRBs) need to ensure that regulations are applied 
sensitively for participants whose human biological samples are used for research purposes. 
These regulations include the right of protection from harm, and the ongoing well-being of 





Along with the regulations pertaining to participants, institutional review boards also need to 
ensure that the interests of researchers and research teams are not overlooked (National Bioethics 
Advisory Committee, 1999). This means that research on stored biological samples, or on newly 
collected samples, should be permitted if scientifically and socially justifiable and if there is a 
sound methodology (National Bioethics Advisory Committee, 1999). Research ethics 
committees (RECs) or IRBs need to ensure that both the genetic privacy laws and the values of 
medical research are respected (Gibbons & Kaye, 2007). Bathe and McGuire (2009) make a 
distinction between ‘genetic privacy laws’ and ‘genetic anti-discrimination laws’, and they 
advocate for the latter. Genetic anti-discrimination laws arise from the misuse of information 
obtained from individuals’ genetic information by the researcher or unintended and unknown 
third parties (Bathe & McGuire, 2009). Such third parties may include government, health 
insurers, and employers, who may discriminate against individuals based on disease 
susceptibility or behavioural predispositions, as indicated by medical research (Bathe & 
McGuire, 2009). 
 
3.2.2 Scientific/social value 
According to Simitis (2004), biobanks should not only be primarily viewed from the perspective 
of dangers and risks, but should instead be viewed in terms of their social utility. Initially, when 
considering the values pertaining to individual privacy and those pertaining to medical 
research/research on human biological samples, they may appear to be conflicting (Gibbons & 
Kaye, 2007; Simitis, 2004). However, it is important rather to see how these work together in the 
pursuit of the public interest (Gibbons & Kaye, 2007). For example, the key function of medical 
practitioners (as outlined in their professional ethics) is protecting and promoting the welfare of 
their patients (Simitis, 2004). Since one of the core aims of biomedical research is to help 
improve future care of presently unknown beneficiaries/ patients, this means that doctors can be 





The ethics surrounding the issue of research on stored biological samples should ensure that 
public interest or social value (e.g. scientific, medical, and public health research) and autonomy 
are of paramount importance (Bauman et al., 2003; Gibbons & Kaye, 2007; Simitis, 2004). By 
autonomy, Bauman et al. (2003) refer specifically to ongoing respect for participants and 
informed consent. An individual’s choice to donate samples can be seen as their expression of 
solidarity and moral duty to help future unknown beneficiaries (Simitis, 2004). According to 
Simitis (2004), this solidarity should entail a realisation by individuals that they too have 
benefitted from others’ donations (of samples for medical research). Thus, it can be argued to be 
a moral obligation to donate one’s own samples to potentially alleviate the suffering of others 
(Simitis, 2004). Simitis (2004) holds that voluntariness is important in maintaining public 
confidence and in emphasising the legitimacy of research, and he believes that this should work 
together with moral obligation.  
 
A conflicting relationship can possibly be identified between the principles of autonomy and 
solidarity/social value (Bauman et al., 2003). This is because obtaining re-consent for use of 
stored biological samples for future unknown research can be financially impossible and it can 
also be seen as an intrusion on individuals’ privacy; yet, at the same time, this research is 
beneficial to the larger public and holds social value (Bauman et al., 2003). Bathe and McGuire 
(2009) acknowledge that using stored samples may be counter to one’s autonomy. They in turn 
argue that since these samples are such a valuable source of scientific knowledge and medical 
management of human disease, it would be difficult to justify discarding them (Bathe & 
McGuire, 2009). They do, however, emphasise that if consent is not obtainable, then researchers 
need to ensure that tissues are coded (Bathe & McGuire, 2009). 
 
When research is intended on stored biological samples, it is often difficult to obtain consent due 
to the financial/economic constraints involved and there is also a potential difficulty or even 
impracticability in re-contacting participants, especially in cases where some may be deceased 
(Bathe & McGuire, 2009). There is also an issue of selection bias which could be a result of not 
being able to reach all participants, and this could affect the scientific validity of the research 
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(Bathe & McGuire, 2009). In light of the above, Bathe and McGuire (2009) conclude that, since 
the use of stored samples for research purposes contributes to the future care of future patients 
and that it is beneficial to society, then it can be considered acceptable to use them without 
participants’ consent. Bauman et al. (2003) suggest that, in making laws governing the collection 
of human biological samples and governing research on stored biological samples, it is important 
to consider both individual autonomy and the common good as mutually beneficial. In saying 
this, Bauman et al. (2003) stress that donated and/or stored samples should be used to their 
fullest potential, provided that results are not misused by the researcher or any unintended third 
party. 
 
3.2.3 Favourable risk/benefit ratio 
When pursuing their scientific aims, researchers need to ensure that the rights and dignity of their 
participants are protected throughout the duration of the study (National Bioethics Advisory 
Committee, 1999). Risks and benefits need to be reviewed continuously, and it is the 
responsibility of the researcher to inform participants of any potential new risks that may arise 
(National Bioethics Advisory Committee, 1999). It is important for researchers also to take into 
account non-physical risks that may arise in the process of research on stored human biological 
samples (National Bioethics Advisory Committee, 1999). By non-physical risks, the National 
Bioethics Advisory Committee (1999) refers to clinically relevant information about individuals 
that could lead to genetic discrimination.  
 
Although biobanks and biomedical research are extremely useful in medical and pharmaceutical 
research, they may invoke feelings of anxiety and distrust for participants or donors (Simitis, 
2004). These anxieties may be due to issues regarding donor protection and the prospects of 
unknown and uncontrolled research on samples; confidentiality and anonymity; and the risks 
associated with the proposed research (Simitis, 2004). According to Simitis (2004), when dealing 
with individuals’ samples, it is important for researchers to realise that these samples contain 
personal information such as disease susceptibility, behavioural predispositions and certain 
aspects of personality. Ensuring protection from genetic discrimination becomes significantly 
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more difficult with research on stored samples because these are usually stored over long periods 
of time for unknown future research (National Bioethics Advisory Committee, 1999). For this 
reason, Simitis (2004) believes that necessary measures need to be taken by lawmakers to ensure 
protection from discrimination and stigmatisation of individuals and/or population groups by the 
researcher or any third parties (Bathe & McGuire, 2009).  
 
In order to minimise risks associated with research on stored biological samples, it is suggested 
that databases containing information related to tissue and to clinical data should be coded, 
which means excluding any personally identifying phenotypic information (Bathe & McGuire, 
2009). Limiting access to these databases solely to researchers for legitimate research purposes 
has also been suggested (Bathe & McGuire, 2009). Bathe and McGuire (2009) state that if such 
precautions are implemented properly, then research on stored biological samples should be 
considered as no more than a minimal risk. 
 
When evaluating biomedical research in terms of social justice, one needs to consider the 
possible injustice of risks being imposed on certain individuals or population groups by using 
their samples for future unknown research from which they are not likely to benefit (Simitis, 
2004). Simitis (2004) raises the question of whether or not benefits from the use of their samples 
should be shared with individuals and how this can be achieved. Those who stand to benefit the 
most from a research study should ideally bear the risks; however, this does not justify 
unnecessary risk being imposed on individuals. Furthermore, benefits need to be shared with 
those who contribute to the research and this process should not be delayed (Simitis, 2004). 
Anonymisation and confidentiality pose a challenge to benefit-sharing and informing participants 
of potential harms of new research on stored biological samples (Bauman et al., 2003). 
Anonymisation, coupled with distance and time, makes it almost impossible to find participants 






3.2.4 Informed consent 
One of the fundamental elements of an individual is self-determination, which is their right to 
make choices regarding themselves, their bodies, and their personal space (Simitis, 2004). This 
right is especially important in biomedical research which involves the use of individuals’ 
biological samples (Simitis, 2004). In respect of their human dignity, individuals should be 
afforded the opportunity to make informed decisions regarding the use of their samples (Simitis, 
2004). Researchers need to ensure that adequate information is provided to individuals, in a 
language that they can understand, before they may be willing to provide their consent to the use 
of their samples (Simitis, 2004).  
 
When obtaining consent for a proposed research project using human bodily samples, 
researchers need to ensure that this consent is freely given, informed, and specific (Bauman et 
al., 2003). Important information to be included prior to individuals providing their consent is: 
(1) a detailed description of the study, including background information and the objectives of 
the research; (2) an explanation as to which other stakeholders have an interest in the research, 
along with the consequences of the research study and the consequences of participating in the 
research; (3) how the data from the samples will be used; and (4) how samples will be handled 
once the research project is over (Bauman et al., 2003). The information also needs to include the 
possible risks associated with participation in research with one’s samples (Simitis, 2004). In 
addition to this, participation should always be voluntary, and participants should not be coerced 
into donating their samples for research (Simitis, 2004). 
 
It is important for researchers to inform participants of any possibility of their samples being 
used in any research in the future, even if details of the research are still unknown to the 
researcher (Simitis, 2004). This is important as it respects participants’ right to self-
determination (Simitis, 2004). By informing participants, they then have the option to consent to 
the use of their samples, and impose limitations on the types of research that may be conducted 
on their samples (Simitis, 2004). While informed consent is an essential prerequisite for ethical 
research, Gibbons and Kaye (2007) state that obtaining it for research on stored biological 
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samples is not always possible, especially if the details of the future research are not yet known 
during the collection of the samples. According to Brownsword (n.d., in Gibbons & Kaye, 2007), 
since consent is an individual choice, it is morally unjustifiable to include individuals in genetic 
databases, or use their samples without their consent, even if it is of social value or it is for 
public health purposes. From this perspective, researchers and research teams need to ensure that 
explicit consent is provided for research, whether personal information is anonymised or not 
(Gibbons & Kaye, 2007). 
 
According to Bathe and McGuire (2009), using individuals’ samples without their consent is a 
violation of their basic human right of autonomy, especially if religious and cultural beliefs 
require that they be buried with all parts of their body. In some countries such as the United 
States of America, the law states that individuals do not own tissues that have been removed 
from their bodies (Bathe & McGuire, 2009). However, because of issues around invasion of 
privacy and respecting the dignity of individuals, consent is crucial in research as using 
individuals’ samples in published or commercial research to which they have not consented, has 
posed challenges with regard to their samples being the source of intellectual property (Bathe & 
McGuire, 2009). Another reason why informed consent is important is because of culture and 
religious views which may include or imply various beliefs regarding science, research, and 
genetic discovery (Al-Jumah et al., 2011). These views are likely to influence individuals’ 
decisions regarding certain research; thus, informed consent is critical in attempts to respect 
participants’ autonomy (Al-Jumah et al., 2011). 
 
While it may be important to re-contact individuals for consent to subsequent research on their 
samples, sometimes this may in itself be regarded as an invasion of privacy (Bathe & McGuire, 
2009). This becomes especially awkward if the individual is deceased, or if the person requesting 
the consent is unknown to the participant (Bathe & McGuire, 2009). Not being able to reach 
participants for re-consent also poses a threat to the scientific validity of the research due to the 
high dropout rate of participants (Bathe & McGuire, 2009). According to the American Society 
of Human Genetics, researchers need not re-contact individuals for consent if the proposed 
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research on their stored samples is associated with minimal risk (Chen et al., 2005; Porter et al., 
2000). However, since biomedical research is of value to society and serves the public good, 
Bathe and McGuire (2009) suggest that it may be justifiable to re-use individuals’ samples 
without their consent. 
 
It is suggested that, if possible, individuals be provided with full information regarding the 
possible future use of their samples (Bauman et al., 2003). This information should include how 
their samples will be used, the anticipated duration of the use of their samples, how the results 
will be used, and if there are any possible third parties who may be involved (Bauman et al., 
2003). Bauman et al. (2003) further suggest that it can be acceptable for researchers to re-use 
individuals’ samples for subsequent research provided that their samples are duly anonymised 
and that individuals have agreed to this when samples were collected. This raises the importance 
of providing an option for unknown future research when collecting samples, as this removes the 
intrusive need for re-contacting individuals (Bauman et al., 2003).  
 
Upon collection of samples for biobanks, regulating authorities need to ensure that researchers 
explain the complicated nature of research with stored samples (Bauman et al., 2003). This is 
with regard to the protection of the interests of individuals whose samples are used and to the 
consent to future research, the specifics/details of which are not yet known (Bauman et al., 
2003). According to Bauman et al. (2003), re-contacting of individuals should be avoided unless 
there is a justifiable reason. Individuals should, however, be given the opportunity to contact 
researchers or biobanks to query the use of their samples or should they want to express any 
limits to their consent (Bauman et al., 2003). Bauman et al. (2003) also suggest three further 
courses of action with regard to re-contacting individuals about clinically significant results. 
These include positive results being made available to individuals on a priority basis; enabling 
individuals to claim a share of royalties or copyright if their samples contribute to patents; and/or 





The first course of action would only apply to specific groups and would not become the norm 
(Bauman et al., 2003). These groups would strictly include only those individuals who are 
personally affected and concerned by the specific therapeutic research (Bauman et al., 2003). 
Although the ‘sharing of royalties’ is a possible course of action, it is suggested that this trend 
towards individual appropriation of human biological material should be avoided (Bauman et al., 
2003). Reasons for this include the fact that it contradicts the notion of community solidarity 
whereby individuals willingly donate their biological materials for research which could be 
beneficial to the community at large (Bauman et al., 2003). 
 
A challenge can be apparent when collections are of concern to certain groups or communities at 
large, but where ethical issues need to be adapted for individual cases (Bauman et al., 2003). 
Ethically, researchers need to ensure that population studies of such magnitude that they provide 
access to genetic material do not fall into the hands of people who are indifferent to or unaware 
of the ethical principles for research (Bauman et al., 2003). Thus, researchers would need to 
ensure that the research design takes into account autonomy, respect for dignity, and freedom to 
participate - to name but a few (Bauman et al., 2003). The difficulty in trying to apply this in 
studies pertaining to certain groups or communities is that all these ethical issues pertaining to 
individuals could be seen as overly constraining and burdensome to researchers (Bauman et al., 
2003). This poses a threat to scientific progress and the potential benefits of research for 
individuals and society at large (Bauman et al., 2003). 
 
In order to prevent possible misuse of samples, it is suggested that consultative bodies are 
formed to enable individuals to enquire regarding the use of their samples (Bauman et al., 2003). 
This becomes particularly important should an individual wish to know if any medically 
significant results are obtained from their results and if their samples are used in generating a 
marketable product or technique (Bauman et al., 2003). 
 
Campbell (n.d., in Gibbons & Kaye, 2007) supports the idea of ‘broad consent’ as he believes 
that re-contacting participants in order for them to provide consent for new research can be a 
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difficult, expensive, and time-consuming task, that can be viewed as ‘paternalistic’. 
Alternatively, the relationship between the individual and the research team and/or biobanks 
should be one based on trust and respect, whereby individuals may consent to a wide range of 
studies, and still have the appropriate control to refuse certain research (Campbell n.d., in 
Gibbons & Kaye, 2007). According to Caulfield (n.d., in Gibbons & Kaye, 2007) researchers 
cannot simply ignore the issue of obtaining consent for research on stored biological samples 
because they believe that it is time consuming, difficult, or expensive. He argues that ‘broad 
consent’ principles should be executed with caution and careful understanding of their 
implications as they alter the basic human right of autonomy (Caulfield n.d., in Gibbons & Kaye, 
2007). 
 
According to the National Bioethics Advisory Committee (1999), researchers also need to be 
ethical at all times, which means not compromising the rights and welfare of human participants 
when pursuing their scientific aims.  
 
While many acknowledge the importance of informed consent when dealing with human 
biological samples, there appears to be little consensus over what type of consent is sufficient 
and when it should be obtained (Porter et al., 2000; Chen et al., 2005). Some have suggested that 
individuals provide consent each time a new study is proposed on their samples, while others feel 
that a future-consent model is sufficient (Porter et al., 2000; Chen et al., 2005). In this future-
consent model, recommendations have been made to provide individuals with a list of options 
from which they can choose the research for they approve their samples to be used (Chen et al., 
2005; Porter et al., 2000). While a checklist of options appears ideal, arguments over which 
options ought to be included still persist, with some suggesting that individuals be offered a 
certain number of choices of types of research that can be conducted on their samples (Chen et 
al., 2005).  
 
Other analysts do not support the use of prospective consent at all and are of the opinion that 
individuals ought to be given the opportunity to consent for any new research intended on their 
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samples (Chen et al., 2005). The requirement for repeated consent when proposing further 
research on samples leads to the difficulty of obtaining the re-consent as it requires the 
identifying data of the donor (Bauman et al., 2003). This leads to the issue of how these 
identifying details should be archived, and the security obligation biobanks face in maintaining 
anonymity of donor samples (Bauman et al., 2003). In maintaining public trust, guarantees of 
security and anonymity are seen as essential and therefore the need for re-consent in biomedical 
research should be suppressed (Bauman et al., 2003). It is further suggested that archives of 
identifying data should be available for three reasons: firstly, if there is a justifiable need for re-
contact; secondly, to allow donors to find out what has happened to their samples should they be 
interested; and thirdly, to enable and facilitate the process of possible withdrawal from research 
of a donors’ sample should the need arise (Bauman et al., 2003).  
 
When confronted with all these issues it is the responsibility of independent research ethics 
committees (RECs) to ensure that values of ethical medical research are respected and that the 
interests of researchers are not overlooked. (Emanuel et al., 2000; Emanuel et al., 2004). At the 
same time RECs need to ensure that human participants are protected at all times even after the 
initial research is completed (Emanuel et al., 2000; Emanuel et al., 2004). In South Africa, the 
National Health Act (NHAs 72(6(c) gave authority to the National Health Research Ethics 
Council (NHREC) under the National Health Act No 61 of 2003 (Department of Health RSA, 
2015).  This act stated that: 
“Every organisation/institution, health agency and health establishment at which health 
and health-related research involving human participants is conducted, must establish or 
have access to a registered Human Research Ethics Committee (REC) (NHA s 73(1)).” 
(Department of Health RSA, 2015, p. 11). 
 
3.2.5 Ongoing respect for participants 
One of the utmost values that researchers and research teams need to hold is that of respecting 
human dignity (Simitis, 2004). This value is central to the ethical and legal obligations of 
researchers, as it insists that individuals’ freedom be respected, and that they not be treated as 
mere ends to researchers’ needs (Simitis, 2004). Researchers need to ensure that individuals are 
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“respected in their uniqueness; their physical and psychological integrity must be protected” 
(Simitis, 2004, p. 42). This means that self-determination is one of the core components of an 
individual and must therefore be held in the highest regard by biobank managers and researchers 
using human biological samples (Simitis, 2004). Self-determination encompasses respecting 
individuals’ ability to make decisions personally that involve or affect them, or parts of them 
(Simitis, 2004). 
 
With the importance placed on self-determination, Simitis (2004) emphasises that self-
determination, or individual consent alone, are not the only necessary conditions for acceptable 
and justifiable research. Even with the necessary individual consent, it is still unethical for 
researchers to pursue research that may be risky to any unintended third parties (Simitis, 2004). 
When dealing with samples that have been anonymised, or that have never been personalised, 
Simitis (2004) argues that researchers should be able to pursue research without obtaining 
consent. According to Simitis (2004), in such cases public interest takes priority as there are no 
evident personal interests. Simitis (2004) does, however, note that if there are possibilities that 
individuals’ samples may be used for future research, then it is better to obtain consent for this so 
as to respect the self-determination of individuals. In addition to this, researchers have to respect 
any limits on the uses of their samples that donors have declared (Simitis, 2004).  
 
According to Simitis (2004), biobanks can give rise to possible feelings of anxiety and distrust 
within donors regarding the protection of their samples. This is seen to arise from the fear of 
uncontrolled use of samples, the possibility of pressure to assume unreasonable risks, and the 
divulging of personal information (Simitis, 2004). As a result of these anxieties, legal aspects of 
data protection become vital, not only for individual donors but also for entire population groups, 
in efforts to reduce the possibilities of genetic discrimination and stigmatisation (Simitis, 2004). 
 
The ethical principle of autonomy can also be applied when considering whether individuals 
should provide informed consent each time their biological samples are used, and when 
considering how many and which choices individuals should be given with regard to research on 
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their samples (Chen et al., 2005). Allowing individuals to control the use of their samples 
acknowledges and respects them as autonomous persons (Chen et al., 2005). Adequate 
information, voluntariness, consent, and freedom to withdraw ensure autonomy of donors (Chen 
et al., 2005; Simitis, 2004). Therefore, making provision for the above can be considered an 
ethical obligation (Chen et al., 2005).  
 
An effort to archive identifiable details away from samples, unless there is a justified need for 
them to be stored together, addresses the ethical principle of ongoing respect for donors (Chen et 
al., 2005). Alongside this, offering donors the option to access results of research on their 
samples also shows ongoing respect, especially with regard to the dissemination of findings 
(Chen et al., 2005). This ongoing protection also extends to minimising the harms incurred by 
participants, by ensuring the confidentiality of their information, and maximising the benefits by 
sharing the benefits of the research (in the form of information) (Chen et al., 2005).  
 
3.3 Biomedical research in the African context 
3.3.1 Ethical considerations 
Most countries in Africa have been categorised as developing countries due to their vulnerable 
situation as a result of a lack of education, unfamiliarity with medical interventions, extreme 
poverty, and their dire need for adequate healthcare and nutrition (Barsdorf & Wassenaar, 2005). 
During apartheid in South Africa, the health sector drew a distinction between behaving ethically 
with patients and human rights (Baldwin-Ragaven, de Gruchy, & London, 1999). This was done 
by removing human rights as the fundamental aspect of ethics, thus rationalising violations of 
human rights (Baldwin-Ragaven et al., 1999). This differential was driven by preservation of 
self-interest and political convenience, at the expense of others (Baldwin-Ragaven et al., 1999). 
 
Vulnerable populations globally, including the socially powerless and the disadvantaged, have 
historically been subjected to unethical research and exploitation. During the course of apartheid 
in South Africa, ruling institutions of the country violated the human rights of black people as 
they were targeted as research participants for unethical research due to their vulnerability 
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(Baldwin-Ragaven et al., 1999).  This in turn may have led to black South Africans being 
apprehensive about their inclusion in medical research, and has led to a distorted view that 
participation in medical research is not voluntary (Barsdorf & Wassenaar, 2005).  
 
Voluntary informed consent is of the utmost importance in low-income settings, and this consent 
should be obtained not only at the individual level, but also with permission from existing 
structures or authorities such as traditional leaders community leaders, religious leaders, and 
schools (Gikonyo, Bejon, Marsh, & Molyneux, 2008; Molyneux, Peshu, & Marsh, 2004). 
Researchers and research teams need to ensure that potential research participants know exactly 
what they are consenting to (Molyneux et al., 2004). This means consent should be negotiated in 
clear language that the participants are able to understand, and if individuals cannot read or 
write, alternative methods of communicating this information need to be adopted (Gikonyo et al., 
2008; Molyneux et al., 2004). In addition, consent should not merely be a once-off process, but 
should rather be evaluated at different stages of the research process, giving individuals the 
freedom to withdraw (Gikonyo et al., 2008). 
 
The legacy of unethical research on vulnerable populations in Africa and internationally has led 
to a more cautious approach to research involving human participants in developing countries 
(Barsdorf & Wassenaar, 2005). Vulnerability and need often make individuals in developing 
countries more susceptible to exploitation (Barsdorf & Wassenaar, 2005). Thus, ethical 
guidelines have been published by the Council for International Organisations of Medical 
Science (CIOMS) for health research in developing countries to ensure the protection of 
individuals (CIOMS, 2002, in Barsdorf & Wassenaar, 2005). 
 
3.3.2 Laws, regulations and guidelines in South Africa pertaining to biomedical research 
Due to its high rate of infectious diseases such as HIV/AIDS and TB, and the growing number of 
medical researchers, South Africa is considered ‘fertile ground’ for research, and for medical 
research in particular (Moodley, Sibanda, February, & Rossouw, 2014). There has been an 
increase in HIV-related research and biobanking, along with an increase in registered clinical 
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trials from 946 trials in 2010 to 1,390 trials currently (Moodley et al., 2014). Research projects in 
South Africa have included those pertaining to biospecimen collection, analysis, and storage for 
future use (Moodley et al., 2014). Samples have also been exported to developed countries for 
research (Moodley et al., 2014). As is the case in other developing countries and BRICS 
countries, the guidelines and frameworks for the analysis of human biological materials have 
been shaped by institutions in Europe and the USA (Molyneux & Geissler, 2008; Sathar & Dhai, 
2012).  
 
In South Africa, the National Health Act (NHA) [Act No. 61 of 2003] governs the national ethics 
regulations, with Chapter 8 specifically focusing on the legal aspects of the use of human 
biological materials (Sathar & Dhai, 2012). Bodies such as the Health Professions Council of 
South Africa and the South African Medical Research Council have also independently 
published research guidelines specific to professionals in their fields (Sathar & Dhai, 2012). 
Furthermore, The South African Intellectual Property Rights from Publicly Financed Research 
and Development Act (IPR Act) [Act No. 51 of 2008] is responsible for regulating intellectual 
property rights, patents, and benefits that may be applicable to research on human biological 
materials (Sathar & Dhai, 2012). According to the Department of Health RSA (2015) Ethics in 
Heath Research, biological material may be stored in repositories for future research once 
collected. Biological material is regarded as pertaining to personal information thus privacy 
issues should be addressed. It then becomes the role of the REC to ensure that thorough 
provisions are made in consent forms for future research purposes (Department of Health RSA, 
2015). In doing so researchers also need to make clear distinction to participants regarding 
biological materials or data collected for clinical purposes and those collected for research 
purposes (Department of Health RSA, 2015).  
In cases whereby no provision is made for broad consent there are 6 recommendations 
(Department of Health RSA, 2015): 
 
i. “Use of existing or archived material collected for clinical or diagnostic purposes, 
including waste and surplus samples, requires expedited review. The nature of the 
previously obtained consent should be determined to ascertain whether 
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subsequent usage was envisaged and whether it falls within the scope of the 
current proposal. If so, new consent is not required. 
ii. If the scope of the current proposal is different, then new consent may be 
required. 
iii. If samples are anonymous and the results of research will not place any 
individual, family or community at social, psychological, legal or economic risk 
of harm, then new consent is not required. 
iv. If the link to identifiers exists but is not provided to the research team and the 
results of research will not place any individual, family or community at social, 
psychological, legal or economic risk of harm, then new consent is not required. 
v. The person who holds the code of link should sign an explicit written agreement 
not to release the identifiers to the research team. This agreement should 
accompany the submission to the REC. 
vi. If the samples can be linked to identifiers, the REC must decide on a case-by-case 




In South Africa, there has been very little published empirical research on public attitudes to the 
use of human biological samples in research, and the ethical implications of this (Moodley et al., 
2014). It is important to take into consideration that South Africa is a very diverse country 
especially with regard to culture. Therefore, public attitudes to the use of human biological 
samples in research need to be explored widely (Moodley et al., 2014). These views of the public 
are of paramount importance, especially with regard to informing legislature on the use of 
individuals’ samples (Moodley et al., 2014). Therefore, a gap can be seen in the literature in 
relation to South Africa (Moodley et al., 2014). 
 
3.4 Public attitudes to the use of their biological samples 
Medical biobanks are those that have been established for both healthcare and research purposes 
(Hoeyer, Olofsson, Mjomdal, & Lynoe, 2004). As research using tissue samples becomes 
increasingly popular, it has received more legal and ethical attention (Hoeyer et al., 2004). In 
developing policies about the donation and use of human samples, researchers and law-makers 
need to consider public attitudes towards this (Hoeyer et al., 2004). There has been a great deal 
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of research conducted to assess public attitudes to the use of their samples in medical/genetic 
research. This section will describe the findings of some of this research, in chronological order.  
 
3.4.1 Wendler and Emanuel (2002) 
 Consent is one of the key aspects of ethical research, and with regard to research on stored 
biological samples, there is debate over when this consent should be obtained (Wendler & 
Emanuel, 2002). Wendler and Emanuel (2002) conducted a study with 504 participants by means 
of a telephonic survey which aimed at eliciting their views about research on their stored 
biological samples (Wendler & Emanuel, 2002). Nearly two thirds of respondents (65.8%) felt 
that consent was necessary for research on clinically derived and personally identifiable samples, 
while 27.3% of the respondents felt that they would require consent on clinically derived 
samples if the samples were anonymised (Wendler & Emanuel, 2002). With regard to samples 
derived from research, 29% of the respondents said that they would require consent if their 
samples were identifiable, while 12.1% of respondents said they would require consent if their 
samples were anonymised before research commenced (Wendler & Emanuel, 2002). A large 
majority of the respondents (88.8%) did wish to be informed of results of uncertain clinical 
significance (Wendler & Emanuel, 2002). Finally, 91.9% of the respondents felt that it was not 
necessary to impose stricter consent requirements on future research related to a different disease 
(Wendler & Emanuel, 2002). 
 
3.4.2 Hoeyer, Olofsson, Mjomdal, and Lynoe (2004) 
 A quantitative study of 1,000 participants conducted by Hoeyer et al. (2004) aimed to 
understand public attitudes to the use of tissue for genetic research. The results showed that 
participants found the use of their medical records without prior consent to be a greater invasion 
of privacy compared to genetic research (Hoeyer et al., 2004). Individuals wanted to be informed 
about their results, especially if they suggested susceptibility to contracting a disease which 
could be preventable if detected early (Hoeyer et al., 2004). Even if the researcher did not 
initially inform participants that certain types of information could arise from research on their 
samples, individuals still wanted to be informed of this (Hoeyer et al., 2004). However, they did 
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not believe that it was advisable to be informed about diseases that could not be treated. A small 
minority had no desire to be re-contacted for any form of results (Hoeyer et al., 2004).  
 
Although legal and ethical debates have highlighted informed consent as one of the most 
important factors in biobanks, respondents in this study did not rank it as the most important 
issue when assessing research on stored samples (Hoeyer et al., 2004). Important issues in 
ranked order were: that all population groups receive equal access to research results; that the 
research is readily applicable; that corporate interests do not determine the research outlook; that 
confidentiality is protected; that research results are not used for selective abortion; and followed 
last of all by informed consent (Hoeyer et al., 2004). 
 
3.4.3 Kettis-Linblad, Ring, Virbeth, and Hansson (2004) 
A Swedish cross-sectional study was conducted by Kettis-Linblad et al. (2004) which aimed at 
identifying the general public’s perceptions about research involving human tissue, assessing the 
public’s willingness to donate samples to biobanks, and identifying factors associated with the 
public’s willingness to donate samples to biobanks. Most respondents showed a positive attitude 
towards research involving human tissue (Kettis-Linblad et al., 2004). The respondents’ trust in 
different authorities’ capability to evaluate the risks and benefits showed that respondents were 
more likely to trust researchers at university hospitals followed by research ethics committees, 
researchers and laymen, healthcare personnel, industry-based researchers, government 
authorities, county councils, and then lastly, the Swedish Parliament (Kettis-Linblad et al., 2004).  
 
In general, participants showed a willingness to donate samples, with 86% of participants willing 
to donate a blood sample for research purposes and 78% willing to both donation of samples and 
storage for future use (Kettis-Linblad et al., 2004). Factors found to be related to the willingness 
to donate samples were attitudes to genetic research and trust in authorities (Kettis-Linblad et al., 
2004). Age was also seen as a factor, with higher age being associated with willingness to donate 
(Kettis-Linblad et al., 2004). Education and gender were not found to be contributing factors 




3.4.4 Chen, Rosenstein, Hilsenbeck, Miller, Emanuel, and Wendler (2005) 
Amongst researchers, a debate still exists with regard to what type of consent is required for 
research with stored biological samples, with some believing that consent is required every time 
a new study is proposed on stored samples, and others opting for broader consent models. A 
quantitative study consisting of 1,670 participants was conducted by Chen et al, (2005) to assess 
what research participants preferred regarding research on their stored biological samples. 
According to Chen et al. (2005), most research participants were willing to allow their samples 
to be used without restriction if given the opportunity to do so. The study found that this 
willingness was common in all participants in terms of sex, age, and proximity to research 
centres, health status, and prospects of direct benefits (Chen et al., 2005). Although it was found 
that African Americans were significantly less likely to allow the unlimited use of their samples 
compared to other race groups, the majority of African Americans (75%) nevertheless allowed 
the unlimited future use of their samples (Chen et al., 2005). 
 
3.4.5 Wendler, Pace, Ambrose, Talisuna, Maiso, Grady, and Emanuel (2005) 
The first empirical study to research the attitudes of individuals in developing countries 
regarding research on stored biological samples was conducted in Uganda with respondents 
associated with a randomised clinical trial (Wendler et al., 2005). This study found that most 
respondents were willing to contribute a coded sample of their children’s blood for future 
research (Wendler et al., 2005). The study also showed that respondents were also willing to 
allow for the samples to be exported to other countries, and they were willing to allow the 
sample to be used for research on any condition (Wendler et al., 2005). 
 
3.4.6 Abou-Zeid, Silverman, Shehata, Shams, Elshabrawy, Hifnawy, Rahman, Galal, 
Sleem, Mikhail, and Mohharam (2010) 
In a qualitative study pertaining to the collection, storage, and use of blood samples for research 
conducted with 600 adult Egyptian patients receiving medical care at the time, over 80% of 
respondents were willing to donate their blood samples for the purposes of future research 
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(Abou-Zeid et al., 2010). Less than half of the respondents wanted to be provided with the 
opportunity to consent to their samples being stored for future research purposes (Abou-Zeid et 
al., 2010). Forty percent of respondents wanted potential future research on their samples to be 
restricted to the initial illness it was collected for (clinically/research), while 54% of the 
respondents were willing to consent to the unlimited and unrestricted use of their samples and 
did not see the need for consenting for restricted use (Abou-Zeid et al., 2010). 
 
With regard to the storage of linked samples, 89% of individuals wanted to be informed of 
results of uncertain clinical significance (Abou-Zeid et al., 2010). More than half of the 
participants would allow samples which were still linked to be used in genetic research, 
regardless of whether or not confidentiality had been assured (Abou-Zeid et al., 2010). 
According to Abou-Zeid et al. (2010), participants were less willing to donate their samples for 
genetic research because of fears of stigmatisation (individually and population groups) and 
because of concerns about the extent to which their private information would be kept 
confidential (Abou-Zeid et al., 2010). 
 
Egyptian participants did not believe that samples should be kept for a set amount of time, and 
they felt that participants did not need to be given the option to withdraw the use of their samples 
(Abou-Zeid et al., 2010). This study also showed that individuals did not want the right to share 
in commercial profits (Abou-Zeid et al., 2010).  
 
3.4.7 Bussey-Jones, Garett, Henderson, Moloney, Blumenthal, and Corbie-Smith (2010) 
For genetic research to grow and succeed, members of the public need to show solidarity and be 
willing to donate their samples (Bussey-Jones et al., 2010). A qualitative and quantitative study 
assessing ‘the role of race and trust in tissue/blood donation for genetic research’ was conducted 
by Bussey-Jones et al. (2010). In this research, participants in the North Carolina Colorectal 
Cancer Study were surveyed and biological samples were collected from consenting participants 
(Bussey-Jones et al., 2010). Respondents who were unwilling to donate samples were more 
likely to be African American and less trusting of medical researchers (Bussey-Jones et al., 
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2010). These respondents were also found less likely to agree to participating in future genetic 
research (Bussey-Jones et al., 2010).  
 
To understand the relationship between race and trust in donation of samples, open-ended 
qualitative questions supplemented the survey (Bussey-Jones et al., 2010). It was found that 
generic concerns such as needle sticks, inconvenience, discomfort, and mistrust were factors that 
influenced individuals’ decisions about donating their samples (Bussey-Jones et al., 2010). Other 
factors associated with less willingness to consent included African American race, female 
gender, older age, lower income, less education, higher occupation category, and worse health 
status (Bussey-Jones et al., 2010). Although research has shown that individuals associate 
medical research with the development of better healthcare, lower acceptance of research was 
seen in minority groups (Bussey-Jones et al., 2010). Minority groups have cited control of DNA, 
potential misuse of data, racial discrimination, stigmatisation, and unequal access to potential 
benefits as reasons for their unwillingness to participate in medical research (Bussey-Jones et al., 
2010).  
 
3.5.8 Al-Jumah, Abolfotouh, Alabdulkareem, Balkhy, Al-Jeraisy, Al-Swaid, Musaaed, and 
Al-Knawy, 2011 
A quantitative study of 1,051 adult participants conducted at outpatient clinics in Saudi Arabia 
found that 68.8% of respondents had positive attitudes to the potential benefits and ethics of 
research, as well as in the willingness to participate (Al-Jumah et al., 2011). Positive attitudes 
and beliefs towards biomedical research were found to be significantly more prevalent in female 
participants (76.1%) compared to male participants (62.5%) (Al-Jumah et al., 2011). A little over 
half of the participants (57%) agreed that advancements in genetic research were beneficial in 
finding cures for new diseases (Al-Jumah et al., 2011). Little concern was shown with regard to 
research on human genetics tampering with religion (only 12.2% agreed it was tampering with 
religion) (Al-Jumah et al., 2011). A small percentage of participants (15.8%) believed that 
researchers were primarily motivated by selfish commercial/monetary reasons (Al-Jumah et al., 
2011). Some participants felt that denying consent to the use of their samples for research would 
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jeopardise their relationship with their healthcare practitioner, and this in turn would impact 
negatively on their healthcare (Al-Jumah et al., 2011). 
 
Most participants (70.1%) were willing to allow the use of their residual samples for future 
research, with willingness being significantly higher in females (77%) than in males (63.9%) 
(Al-Jumah et al., 2011). However, it was found that willingness to donate samples (86.6%) was 
slightly more common in males (88.8%) than in females (84.4%) (Al-Jumah et al., 2011). Only 
27.3% showed willingness to donate organs of deceased family members, and there were no 
significant differences between the sexes in this regard (Al-Jumah et al., 2011).  
 
Age, marital status, current employment status, having children, perceptions of health status, 
presence of chronic disease, previous tissue testing, previous blood donation, and the desire for 
feedback were all found to be non-significant predictors of positive attitudes towards biomedical 
research (Al-Jumah et al., 2011). Factors found to be significant predictors of positive attitudes 
to biomedical research were sex, education, having had a previous blood test, and previous 
participation in health-related research (Al-Jumah et al., 2011). Factors found to be significantly 
associated with willingness to allow the use of residual surgical tissue for research were sex, 
history of previous blood tests, and history of previous hospitalisation (Al-Jumah et al., 2011). 
Females and those who previously had blood tests, those who had a history of previous 
hospitalisation, and those who had previously participated in health-related research were found 
to be twice as likely to allow the use of their residual surgical tissue in research (Al-Jumah et al., 
2011).  
 
3.4.9 Halverson and Friedman Ross (2012)  
Biobank-based research grows in importance alongside the debate of the return of results to 
individuals and population groups (Halverson & Friedman Ross, 2012). Halverson and Friedman 
Ross (2012) conducted a mixed-methods study to assess the attitudes of African American 
parents about biobank participation and the return of research results for themselves and their 
children (Halverson & Friedman Ross, 2012). It was found that most parents would enrol 
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themselves and their children in a biobank (Halverson & Friedman Ross, 2012). However, a 
small minority were reluctant to enrol their children (especially young children), as they felt it 
was necessary to involve them in the decision-making process (Halverson & Friedman Ross, 
2012).  
 
Most of the participants (97%) showed equal levels of interest in receiving their results and those 
of their children, and several participants rejected the idea of children having a right to keep 
healthcare information private from their parents (Halverson & Friedman Ross, 2012). 
Generally, most participants believed that children should be given the right of access to their 
health information, but parents wanted to be involved in deciding when and how the information 
was shared (Halverson & Friedman Ross, 2012). 
 
3.4.10 Opinion Leader (2012)  
A mixed-methods study was conducted by Opinion Leader in 2012 to assess public attitudes to 
health-related research. Qualitative findings were obtained by means eight focus groups with the 
general public and twenty in-depth interviews with research participants and people affected by 
medical conditions (Opinion Leader, 2012). The quantitative results were obtained by means of a 
survey of 1,105 members of the general public (Opinion Leader, 2012). There were five main 
areas of focus, namely: the public’s attitude towards participation in medical research; the 
benefits and harms of receiving feedback; when health-related findings should not be fed back; 
how health-related findings should be addressed in the consent process; and the mechanisms of 
feedback of health-related findings (Opinion Leader, 2012).  
 
The qualitative and quantitative findings showed different results and it was evident that 
participants had varying perceptions about medical research (Opinion Leader, 2012). In the 
qualitative aspect of the study, participants generally viewed medical research as negative, and 
associated medical research with drug trials and testing involving human and animal subjects 
(Opinion Leader, 2012). In the quantitative results, however, more positive views were expressed 
about medical research and participants felt that the advantages of medical research outweighed 
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the disadvantages (Opinion Leader, 2012). Participants were found to be more trusting of 
medical doctors and scientists working in universities in conducting medical research, as 
opposed to pharmaceutical companies (Opinion Leader, 2012). These results are similar to those 
obtained by Ketttis-Linblad et al. (2005). 
 
Participants saw more benefits than harms in receiving feedback, and cited reasons such as: early 
detection of conditions, psychological preparation for illnesses, and benefits for relatives in being 
prompted to screen for risk of developing similar conditions (Opinion Leader, 2012). The 
severity and treatability of the condition were found to have the strongest influence on 
participants wishing to receive feedback (Opinion Leader, 2012). Clinically trained researchers 
had more of an obligation to provide feedback on health-related findings as opposed to 
researchers, who were not clinically trained (Opinion Leader, 2012). 
 
This study also focused on establishing how participants felt health-related findings should be 
addressed in the consent process (Opinion Leader, 2012). It was found that individuals would be 
more likely to take part in a study if it was made clear how the health-related findings would be 
used, as this would help them in making an informed decision (Opinion Leader, 2012). This was 
seen as critical in the consent process (Opinion Leader, 2012). Some participants felt that it was 
important for researchers to give individuals a choice as to whether or not they wish to receive 
feedback (Opinion Leader, 2012). However, most people felt that, regardless of a person’s 
preference, researchers were obligated to provide feedback if they had a condition that could 
harm others or themselves (e.g., an infectious disease) (Opinion Leader, 2012). Participants felt 
that the best way to receive feedback was via face-to-face discussions, especially if an individual 
was found to have a life-threatening or unmanageable condition (Opinion Leader, 2012). 
Participants also showed a preference for receiving results from someone with medical 






3.4.11 Moodley, Sibanda, February, and Rossouw (2014)  
To date, there has been very little research conducted in South Africa that assesses the public’s 
attitudes to health-related research (Moodley et al., 2014). This has ethical considerations as it is 
the perspectives of individuals that should inform guideline development (Moodley et al., 2014). 
Moodley et al. (2014) sought to explore South African research participants’ attitudes to the use, 
storage, and exportation of their biological samples. Data was obtained by means of a semi-
structured survey which elicited both quantitative and qualitative results; 200 participants 
responded (Moodley et al., 2014).  
 
While individuals supported the collection and storage of samples, they also showed strong 
views about storage and future use, export, and benefit-sharing (Moodley et al., 2014). 
Underlying many of the participants’ views was the concept of ownership (Moodley et al., 
2014). Only half of the participants favoured the one-time broad consent model, while the other 
half felt that consent should be sought for new studies proposed, and that RECs could not decide 
on their behalf (Moodley et al., 2014). A small percentage of individuals (19.5%) did not wish to 
share the profit if the research was conducted for a good cause, while 39.5% said that they would 
mind if a profit was made (Moodley et al., 2014). Of the 39.5%, 43% wanted a share of the 
profit, while 56% said that they would be very unhappy about profits being made from their 
samples (Moodley et al., 2014).  
 
Most participants were comfortable with their samples being exported from South Africa; 
however, 10% of the participants expressed strong views of discomfort with regard to exporting 
their samples to other African Countries and to developed countries (Moodley et al., 2014). This 
study also explored the concept of ownership and what emerged was that, while some 
participants refer to samples in the context of donation, many still showed a sense of ownership 
by using phrases such as “my blood” (Moodley et al., 2014). This sense of ownership was 
consistent with views of needing to be re-contacted every time samples were being used and 





While the importance of biomedical research on human biological samples cannot be denied, it is 
important for researchers and research teams to be equally aware of the ethical guidelines from 
the conceptualization of a research study throughout till after the study is complete (Emanuel et 
al., 2000; Emanuel et al., 2004).  
 
Throughout history, many atrocities have been committed on human participants by researchers 
in pursuit of scientific aims. Individuals were treated as a ‘means to specific ends’ (Emanuel et 
al., 2000; Emanuel et al., 2004; Wassenaar, 2006; Wassenaar & Mamotte, 2012). As a result of 
this unjust treatment of human research participants, guidelines for ethical conduct were 
developed to avoid recurrence of past abuses. Central to all of these ethical guidelines is the 
obligation of researchers and RECs/IRBs to ensure that the welfare of research participants is 
protected throughout the research process (Emanuel et al., 2000; Emanuel et al., 2004; 
Wassenaar, 2006; Wassenaar & Mamotte, 2012). 
 
 
Human biological samples are invaluable for medical and pharmaceutical research, but they 
contain confidential and clinically relevant information on individuals that has the potential to be 
misused (Elger & Caplan, 2006). This makes it even more important for there to be suitable and 
efficient frameworks that safeguard the rights of individuals and that also promote beneficial 
research for the public good (Gibbons & Kaye, 2007; Porter et al., 2000). Ethical issues in 
biomedical research should be thought of within the framework of the eight ethical guidelines. 
When samples or residual samples are obtained and stored (for current and/or prospective 
research), RECs and IRBs need to ensure that regulations are applied sensitively for participants 
whose human biological samples are used (National Bioethics Advisory Committee, 1999; 
Simitis, 2004). Arising from this is: 
 knowing whether participants require consent for the future use of their samples  




 whether participants consent to the unlimited use of their samples  
 whether results of research could lead to any forms of genetic discrimination against the 
individual or their population group  
 whether clinically significant results need to be reported to research participants 
 whether individuals wish to share possible economic benefits from their samples.  
 
In establishing policies and regulations about the donation and use of biological samples, law-
makers need to take public attitudes into consideration. Many studies have been conducted 
internationally to assess public attitudes to the use of samples in medical/genetic research. 
Studies have shown that individuals are willing to donate their samples and would not mind their 
samples being used without consent as long as samples are not personally identifiable (Abou-
Zeid et al., 2010; Al-Jumah et al., 2011; Chen et al., 2005; Halverson & Friedman Ross, 2012; 
Hoeyer et al., 2004; Kettis-Linblad et al., 2004; Moodley et al., 2014; Opinion Leader, 2012; 
Wendler & Emanuel, 2002; Wendler et al., 2005).  
 
One study also showed that participants were willing to allow for samples to be exported to 
others countries (Wendler et al., 2005). Willingness to donate was found to be related to attitudes 
to genetic research and trust in researchers, which was found to be lower among African 
Americans (Bussey-Jones et al., 2010; Chen et al., 2005; Kettis-Linblad et al., 2004). Factors 
such as education, race, sex health status, income were unrelated to willingness to donate 
samples. (Al- Jumah et al., 2011; Bussey-Jones et al., 2010; Chen et al., 2005; Kettis-Linblad et 
al., 2004).  
 
With regard to consent, studies showed that participants were happy to provide broad consent for 
the use of their materials (Chen et al., 2005; Wendler & Emanuel, 2002). However, in Moodley 
et al. (2014), participants showed a greater sense of ownership of their samples and only half 




Most participants wanted to be informed of results of clinical significance, especially if there is a 
susceptibility to contracting a disease that is preventable through early detection (Abou-Zeid et 
al., 2010; Hoeyer et al., 2004; Opinion Leader, 2012; Wendler & Emanuel, 2002). One study 
showed that individuals did not wish to receive their results if they contained information about 
an incurable disease (Hoeyer et al., 2004; Opinion Leader, 2012). One study showed that 
individuals did not want the right to share in commercial profit (Abou-Zeid et al., 2010), whilst 
another study showed that individuals held strong views on benefit-sharing (Moodley et al., 
2014). 
 
Although there is substantial research published on public attitudes towards biomedical research, 
a gap exists in South Africa as very little literature has been published (Moodley et al., 2014). 
Given the high rate of infectious diseases in Africa, and the growing rate of highly skilled 
medical researchers, African countries should be flourishing scientifically. The views of the 
public are important in informing legislation which is in line with people’s views, beliefs and 
needs (Moodley et al., 2014). As seen in the Moodley et al. (2014) study, it is evident that South 
Africans hold strong views about the storage and future use, export, and benefit-sharing of 
human biological samples. It is also evident that South Africans show a strong sense of 
ownership of their materials (Moodley et al., 2014). Thus, it is important that studies such as 
these are conducted both quantitatively and qualitatively in order to assess and gain an in-depth 
understanding of whether these views are common among most individuals in this country. This 
study hopes to contribute to addressing this gap in the South African data. 
 
Chapter 4: Aim and rationale 
 
The aim of this study was to quantitatively explore public attitudes towards the collection and 
storage of human biological samples for future research purposes. For the sake of this research, 
the public was defined as those individuals from whom human biological samples could be 
obtained. In South Africa to date, there has been very little published empirical research that 
focuses on public attitudes to the use of their biological samples in research (Moodley et al., 
 
 44 
2014). Knowledge of public attitudes towards research with human biological samples is 
important as it provides key ethical aspects of participant perspectives towards this type of 
research (Moodley et al., 2004). Therefore, in developing guidelines and regulations about the 
use of human biological samples, law-makers need to take relevant public attitudes into 
consideration. 
 
The rationale for this research was to develop a better understanding of people’s attitudes 
towards the use of their biological samples. Given the great cultural, social, geographical, and 
economic diversity in South Africa, these attitudes are important in informing guideline 
development, research ethics deliberation, and legislation which is in line with people’s views, 
beliefs, and needs. 
 
4.1 Questions to be answered by research  
The main question this research sought to explore was regarding public attitudes towards the 
collection and storage of human biological samples for future research purposes. In order to 
answer the above question, the following three sub-questions were used: 
 Do individuals from whom stored biological samples were obtained think their consent 
should be required for future research?  
 Do they want to receive results of clinical significance? 
 What are people’s perceptions of confidentiality? 
 
The researcher was also interested in finding out the following: 
 Is there a significant association between any of the socio-demographic variables and the 
above questions? 







Chapter 5: Methodology 
 
5.1 Research design 
A research design is a strategic framework which researchers use to fulfil the purpose of the 
research (Durrheim, 1999; Peil, 1982; Robson, 1993). This framework enables researchers to 
conceptualise research questions in order to obtain the information that is sought (Durrheim, 
1999; Peil, 1982; Robson, 1993). Furthermore, it also provides a plan for which data is collected, 
analysed, and interpreted within research (Durrheim, 1999; Peil, 1982; Robson, 1993). For the 
purpose of this research, a quantitative research design was adopted. According to Punch (2013), 
the main aims of quantitative research are to conceptualise reality in terms of variables; to 
measure these variables; and to study relationships between these variables. This framework was 
most suitable as the researcher was interested in a larger scale study. Quantitative methods are 
most useful in large-scale studies as they are efficient for communicating numbers and this made 
this approach most suitable for this research.  
 
The style of quantitative research that was used in this study is descriptive research by means of 
a cross-sectional survey. Descriptive research aims at describing social phenomena of interest 
and the distribution of attributes in a population (Durrheim, 1999; Robson, 1993; Schutt, 1996; 
Tredoux, 1999). The social phenomenon that the researcher was interested in was public 
opinions about the collection, storage, and use of human biological samples for future research 
purposes. Cross-sectional surveys focus on the make-up of the sample and on the state of affairs 
in the population at one point in time (Robson, 1993). The specific make-up of the sample in this 
study was out-patients who were currently accessing medical care at the major government 
hospitals in Pietermaritzburg. According to Robson (1993), surveys are useful in answering 
questions of what, who, where, how many, and how much. Surveys can also be useful in 
exploring aspects of a situation, or in seeking explanation and providing data for testing 






5.2.1 Sampling method 
For the purpose of this study, probability sampling was used. Probability sampling is where the 
probability of the individual being chosen is known (Peil, 1982; Robson, 1993; Schutt, 1996). 
The advantages of using probability sampling are that, firstly, the chances of selection bias by 
the researcher are removed, and secondly, the accuracy of samples may be estimated through the 
application of the principles of probability theory (Mouton, 1996). This type of sampling is 
considered to be representative sampling and allows researchers to make probabilistic 
generalisations from the sample to the population (Peil, 1982; Robson, 1993; Schutt, 1996). 
 
The specific probability sampling technique that will be used to select participants will be simple 
random sampling which involves the selection of participants at random from the population of 
interest (Peil, 1982; Robson, 1993; Schutt, 1996; Seale, 2012). This technique ensures that all 
participants have an equal chance of being chosen to participate (Peil, 1982; Robson, 1993; 
Schutt, 1996; Seale, 2012). This sampling approach was most useful given that the population 
was quite large. A handful of participants were selected from waiting areas from the various 
departments of hospitals on different days. 
 
5.2.2 Recruitment of participants 
For the purpose of this research, 200 participants were recruited. These participants were all out-
patients at Pietermaritzburg government hospitals. Approximately one hundred participants were 
randomly selected from each of two government hospitals in Pietermaritzburg, namely Grey’s 
Hospital and Edendale Hospital. In the initial proposal, the researcher had aimed to recruit fifty 
participants from each of the three major government hospitals in Pietermaritzburg; this included 
the two abovementioned and Northdale Hospital. Due to the non-response from Northdale 
Hospital, the researcher was forced to exclude this site from the study. The researcher then chose 




The inclusion criteria were adult males and females in the hospital waiting area who were willing 
and competent to consent. Persons accompanying patients were also approached if they were 
willing and competent to consent. The exclusion criteria were minors, adults unwilling and 
unable to consent, and obviously distressed or uncomfortable patients. The reason for this 
particular sample was that the researcher was interested in people who were currently seeking 
some sort of medical attention in one of the Pietermaritzburg government hospitals, as they were 
likely at some point to be required to provide their human biological samples for clinical 
purposes. This makes their current attitudes to the possible collection and storage of their 
samples relevant to this cross-sectional survey. 
Participants were recruited in the various waiting rooms of the different medical departments of 
the two hospitals. In each of the waiting rooms, the first thing that the researcher did was 
approach the nursing sister in charge to explain the study and show the relevant documentation 
(consent from the relevant bodies and from the hospital management). This was done to ensure 
that the hospital staff were aware of the researcher so that the researcher would not impinge on 
the normal day-to-day functioning of the hospital. Once staff were addressed, the researcher 
explained the study to those in the waiting area and those who were willing to participate showed 
their interest by raising their hand.  
 
Recruitment of participants and data collection happened over the course of two weeks. Each 
weekday, the researcher attempted to collect at least five surveys from each waiting area of a 
hospital. The reason for the collection being stretched out across the five days in each of the 
hospitals was because sometimes in government hospitals, certain illnesses are dealt with only on 
certain days; therefore, the researcher wanted to ensure that the sample was diverse, that 
individuals had a fair chance of being selected, and that certain people were not excluded due to 







5.3 Ethical considerations 
5.3.1 Independent ethical review 
In order to ensure the protection of human participants and enhance the quality of this research, it 
was necessary for the researcher to obtain ethical clearance prior to the commencement of this 
research (Emanuel et al., 2000; Emanuel et al., 2004; Wassenaar, 2006). This was done firstly 
through the submission of a research proposal internally to the University of KwaZulu-Natal 
College of Humanities Research and Higher Degrees review panel. Provisional approval was 
obtained from this review panel (Appendix A subsequently, the proposal had to be submitted to 
the University of KwaZulu-Natal Biomedical Research Ethics Committee. Once the proposal 
was approved by this committee (Appendix B,), the researcher was able to approach the 
KwaZulu-Natal Department of Health and the hospitals for gate-keeper permissions (Singh & 
Wassenaar, 2016). 
 
5.3.2 Gate-keeper permission 
Prior to the researcher being able to enter the hospitals to recruit participants for participation in 
the study, it was necessary to obtain permission from the gate-keepers, namely the KwaZulu-
Natal Department of Health and the CEOs of both of the hospitals. Permissions were sought in 
writing and in personal meetings with the CEOs and medical managers. Once they were both 
obtained (Appendix C and D), the researcher was then able to apply for permission from the 
KwaZulu-Natal Department of Health. This application was submitted online and permission 
was obtained (Appendix E).  
 
5.3.3 Informed consent 
When individuals were invited to participate, the study was first explained to them verbally, then 
further by an information sheet This verbal explanation and the information sheet were provided 
in both English and isiZulu, as not all participants were able to understand and read English. This 
information sheet made clear all the information regarding the study, its methodology, and the 
potential risks and benefits that are directly or indirectly associated with participation. It also 
highlighted the fact that participation was entirely voluntary, and that they had the freedom to 
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decline to participate, or to withdraw once the study had started, without any negative 
consequences to themselves. According to Emanuel et al. (2000), Emanuel et al. (2004), and 
(Wassenaar (2006), informed consent requires the provision of appropriate information, the 
competence and understanding of participants, and that participation is voluntary and uncoerced. 
Attached to this information sheet was the consent form which was also provided in both English 
and isiZulu for the same reasons as above ((Appendix F and G). 
 
5.3.4 Potential risks or harms and benefits 
Through participation in thus study, no risks or harms - whether biological, psychological, social, 
legal or financial - were incurred by the participants. Participants, however, did raise questions 
about research on human biological samples and these questions were answered as soon as they 
were brought to the researcher. No costs were incurred by participants in participation for this 
research except for the time it took for them to complete the survey (approximately 10 minutes). 
Participants did not lose their places in clinic queues if they participated in the study. 
 
There were also no direct benefits to participants who participated in this study, nor were there 
any incentives offered (due to budget constraints); however, through participation in this study, 




The researcher took the necessary measures to ensure that confidentiality was maintained 
throughout the course of the research. Firstly, participants’ surveys had no names or personal 
identifying details written on them, so as to keep responses anonymous. Instead, all answered 
surveys were coded and each participant was given a unique code. Secondly, the individual 
survey responses were stored separately from the information sheet and consent forms, for the 
same reason. Some participants preferred to have the researcher read out the survey to them so as 
they could answer it verbally and have it filled out on their behalf. In instances such as these, 





5.3.6 Dissemination of results 
Results from this research have been written up in the form of a dissertation in partial completion 
of a Master’s Degree by the researcher. A copy of this dissertation will be available at the 
University of KwaZulu-Natal Pietermaritzburg Campus Cecil Renaud Library and may hopefully 
published in a peer-reviewed journal. Results will also be forwarded in the form of a report to the 
KwaZulu-Natal Department of Health Research Committee. 
 
5.3.7 Data storage 
Hard copies of surveys and consent forms were scanned and are stored electronically in a 
password-protected folder by the researcher. Statistical data and analyses are also stored in the 
same password-protected folders to ensure that they are not accessed by any unintentional third 
parties. All this data will be backed up in password-protected cloud storage space in case the 
hard drive is lost or damaged in any way. Hard copies of all the surveys and consent forms will 
be incinerated so as to avoid any risks of breach of confidentiality. 
 
 
5.4 Data collection 
Data was collected by means of a survey at two local government hospitals in Pietermaritzburg, 
namely Grey’s Hospital and Edendale Hospital. In each of these hospitals, one hundred 
outpatients were recruited from the various waiting areas. At each of the waiting areas, the 
nursing sister in charge was approached to inform the patients in queues about the researcher. 
Thereafter, the researcher explained the study to the patients and those who were interested in 
participating in the study were given an information sheet and consent form, then the actual 
survey. As stated previously, some of the participants preferred to have the survey read out to 
them with them providing their responses verbally. In the case of these participants, they were 




5.4.1 Data collection tool 
Data was collected by means of a survey. This was a pre-existing survey that was obtained from 
literature and was adapted to suit the needs of this study. Permission to use the survey was 
sought from Dr. D. Wendler via email (Wendler & Emanuel, 2002)  
The original survey (Appendix H) was intended for two cohorts - namely older individuals at 
four geographically dispersed US research centres who have a first-degree relative with probable 
Alzheimer’s disease, and randomly selected Medicare beneficiaries (Wendler & Emanuel, 2002). 
The inclusion criteria were that participants were required to be 50 years or older, able to speak 
and understand English, able to understand the survey questions, and be able to hear well enough 
to respond to questions over the phone (Wendler & Emanuel, 2002).  
In order for this survey to be relevant for the current research, the researcher had to make a few 
changes to adapt it to suit the current needs. The original survey was broken up into five sections 
namely: (1) research and clinical experience; (2) consent/research on stored samples; (3) 
perceptions of confidentiality; (4) socio-demographic; and (5) conclusion. For the purpose of this 
study, this general format was kept; however, content was changed in some places. 
 
The first part of the original survey focused on getting an understanding of participants’ past 
experiences of having an Alzheimer's disease test using their blood or saliva. For this study, the 
researcher made a choice to shift the focus away from Alzheimer’s disease and asked 
participants of their experiences of having any test run using their biological samples (not limited 
to blood and saliva). Clear examples of human biological samples were listed so participants had 
an understanding of what was meant. A total of 9 questions that were specific to Alzheimer’s 
disease and that could not be adapted were left out. Nine other questions were adapted slightly to 
move away from Alzheimer's disease.  
 
The second part of the original survey focused on consent and research on stored samples. 
Various hypothetical scenarios were given to participants about future research on research-
derived residual samples. For this study, the researcher chose to include six additional questions 
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that addressed clinically derived residual samples. Other questions that addressed one-time 
general consent and providing limits to the use of one’s samples were included. 
 
No changes were made in the third section of the original survey regarding perceptions of 
confidentiality. Minor changes were made in the fourth socio-demographic section. These 
changes were made according to the Stats SA format of categories and groupings in South Africa 
(e.g., race groups, religious groups, income brackets, levels of education, etc.). 
 
The fifth section of the original survey was the conclusion which asked participants how they felt 
about the survey and whether they had experienced any stress resulting from participation in this 
study. This remained unchanged as well; however, it was not included in the overall analysis as it 
was more not directly related to the current research.   
 
The final English survey (Appendix I) was simplified as much as possible and it was also 
translated into isiZulu since it is the main language in KwaZulu-Natal. The isiZulu version was 
given to three first-language speakers to read independently, and corrections were made and a 
discussion was held to ensure that everyone understood the questions in the same way (Final 
IsiZulu survey- Appendix J). 
 
5.5 Data analysis 
Data obtained from the surveys was analysed in various stages. Firstly, it was necessary for the 
researcher to check all the surveys individually to ensure that participants had filled them out 
correctly. Secondly, the researcher had to create a codebook and give each variable (question) a 
unique SPSS variable name and a coding instruction (Appendix K). This was followed by the 
researcher entering the data onto a Microsoft Excel spreadsheet for analysis using SPSS at a later 
stage. Using Microsoft Excel meant that the researcher was able to enter the data as it would 
appear on SPSS; however, defining the variables and providing coding instructions were only 
available on SPSS and this was the next step. Once that had been done, it was necessary for the 




For the purpose of this research, univariate and bivariate analysis were used. Univariate analysis 
was necessary for obtaining frequency counts of single variables. This was followed by bivariate 
analysis which was necessary for obtaining cross-tabulations between the dependent (main 
research questions) and independent variables (socio-demographic variables and previous 
clinical experience) in order to analyse for patterns and relationships. The chi-square test of 
association was used to analyse whether there was a significant association between the 
dependent and independent variables. The assumptions of this test are that (1) the two variables 
should be measured at an ordinal or nominal level, and (2) the two variables should consist of 
two or more categorised independent groups. The null hypothesis states that there is no 
significant association between the sets of the categories.  
 
Pearson chi-square was used as a test for association, and confidence levels were set at 95% 
(p=0.05). When interpreting the output, it was necessary for the researcher to check whether 
assumptions had been violated. If the minimum expected cell count is less than 5 or 20% of cells 
have an expected count of 5, then assumptions have been violated. In this case, the better 
measure of association would be the Likelihood Ratio figure. The measure of association was 
also calculated and reported (Cramer’s V; 95% confidence intervals). 
 
5.6 Reliability, validity and rigour 
The questionnaire that will be used from this study was obtained from literature. A pre-existing 
questionnaire was obtained from Wendler and Emanuel (2002) and was adapted to suit the South 
African population and the needs of this study. With regard to reliability and validity of this 
instrument; the questionnaire development in the original study occurred over a series of seven 
steps namely: (1) comprehensive literature review (2) draft survey development (3) review by 
experts in survey methodology genetics research (4) survey revision (5) cognitive pre-test using 
in-person interviews with 3 elderly individuals who were participating in clinical research in the 
Boston area (6) behavioural pre-test with 3 additional elderly individuals who were participating 
in clinical research in the Boston area  (7) final revision (Wendler & Emanuel, 2002). 
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Furthermore, it was approved by the institutional review boards at UCLA, Stanford University, 
Duke University, the National Institute of Mental Health, and the University of Massachusetts, 
Boston (Wendler & Emanuel, 2002). Validity and reliability of this questionnaire in the South 
African context have not been tested. 
 
 
5.7 Limitations of the design 
The original study noted four limitations of the design. The first limitation in the original study 
was regarding the low response rate for the Medicare cohort and how this affected 
generalizability of the research results (Wendler & Emanuel, 2002). The second limitation in the 
original study was about the phrasing of identifiable samples as samples ‘with names still 
attached’ in the research questions regarding consent for research on stored samples (Wendler & 
Emanuel, 2002). The authors felt it was necessary for future researchers to include questions 
about research on coded samples (where identifying details are known but not given to 
investigators) as this could have an impact as to whether participants are likely to require 
consent.  The third limitation in the original study was due to the fact that one of the cohorts was 
individuals with a family history of Alzheimer's disease and how this affected their cognitive 
capacities (Wendler & Emanuel, 2002). However individuals were assessed before the study and 
they were Alzheimer's free and competent (Wendler & Emanuel, 2002). 
The last limitation in the original study was due to the fact that participants possibly may have 
little to no understanding of the potential risks and benefits of research on stored biological 
samples thus their (un)willingness may be due to a misunderstanding. This was a limitation of 
this study as well and perhaps future research could focus more on engaging qualitatively with 








Chapter 6: Results 
 
6.1 Introduction 
The first of two sections of this analysis will present the simple descriptive statistics/ frequency 
counts of the participants’ socio-demographic factors and their previous clinical experience 
(independent variables). The analysis will then be presented thematically in sections according to 
the three main research questions (dependent variables) namely: 
 Do individuals from whom stored biological samples were obtained think their consent 
should be required for future research? 
 Do individuals want to receive results of clinical significance?  
 What are people’s perceptions of confidentiality? 
 
In each section, the frequency counts of each of the variables will be reported. The researcher 
will then report of the analysis of significant associations existing between the any of these 
variables (dependent variables) and the above-mentioned independent variables.  
 
6.2 Participants’ socio-demographics  
 
Table 1 below summarises respondents’ socio-demographic details 
 
Table 1. Frequency table of respondent socio-demographics 
 








































































not very religious 











Level of Education 
No schooling 
Primary School ( grade 1 to 7) 






















employed full time 






















Income before taxes 
none 
R1 - R400 









































































6.3 Clinical experience 
With regard to having tests using their biological samples, 86.5% of participants had previously 
had such tests done (Table 2). Of these tests, 28.5% were done less than six months ago; 
followed by 23% that were done between six months and a year ago; 21.5% that were done 
between one year and two years ago; and 13% that were done more than two years ago. About 
three-quarters (75.5%) of the participants received an explanation or discussion about the 
respective test using their biological samples, whilst 7% of participants received no explanation 




Less than half (42.5%) of participants decided to have the test using their biological samples 
done because the explanation prior to the test convinced them, while 31.5% decided to have the 
test done prior to the explanation, and 8% were unsure as to why they decided to have the test 
done. Most participants (70%) felt that everything was discussed sufficiently prior to the test, 
while others (12%) felt that some things were not discussed adequately. Things that were not 
discussed included the reason for the test (6%); living with the disease that they were going to be 
tested for (4%); what they were going to do with the results (0.5%); and some people had 
difficulty understanding because of a language barrier (0.5%). For less than half of the 
participants (40.5%), it was stated very clearly that the test using their biological samples was an 
option. For 26%, it was stated clearly; not very clearly for 8%; not clearly at all for 3%, and for 
3%, it was not reportedly discussed at all. 
 
After the tests were performed, 65.5% of participants had a post-test discussion whilst 20.5% of 
participants did not receive one. Results of the tests were explained very well to 43% of 
participants; well to 30% of participants; not very well to 6% of participants; and not well at all 
to 1.5% of participants. Discussions of how results of the test using their samples might affect 
the families of the participants were done very well for 38.0% of the participants, while 32% of 
participants found them to be done well; 6% found them to be done not very well; 2.5% found 
them to be done not well at all, and for 2% of the participants, these discussions were not held. 
 
Discussions of the possibility of future research using the already collected samples of the 
participants were mostly not done at all (47.5%) or the participants did not recall having these 










According to Simitis (2004), it is an individual’s inherent right to make decisions regarding their 
bodies and their personal space, and this right is especially important in biological research 
which uses individuals’ biological samples. It is therefore important in respect of their human 
dignity for researchers to inform individuals/participants of any possibility of their samples being 
used in any research in the future, to afford individuals the opportunity to make informed 
decisions regarding the use of their samples (Simitis, 2004). While the issue of consent when 
dealing with human biological samples is undeniably important, there are differing opinions over 
what type of consent is sufficient in different situations, and when it should be obtained (Porter 
et al., 2000; Chen et al., 2005). For the purpose of this research, different hypothetical scenarios 
were given to participants regarding research on stored biological samples. The findings were as 
follows (Table 3). 
 
6.4.1 Consent and residual clinical samples - identifiable and unidentifiable 
Most participants felt that consent was necessary for research on residual clinical samples which 
were identifiable (70.5%), while others felt that it was not necessary (20.5%) and some were not 
sure (9.0%). A significant association was observed between consent for residual identifiable 
clinical samples and current employment (Likelihood Ratio=24.886; df=10; p=0.006). Students 
and self-employed individuals were most likely to require consent for research on residual 
identifiable clinical samples. The effect size of this association was considered to be moderate 
and significant (Cramer’s V=0.232; p=0.018). It should be noted, however, that ‘students and 
‘self-employed’ were small groups; therefore, the significance of the association is questionable 
(Figures 1a and 1b).  
 
A significant association was also discovered between consent for residual identifiable clinical 
samples and income before taxes (Pearson chi-square=33.957; df=20; P=0.026). The effect size 
of this association was considered to be strong and significant (Cramer’s V=0.302; p=0.014). All 
participants who had an income over R25601 were unsure as to whether consent was necessary 
for research on residual identifiable samples. With that being said, it is also noteworthy that the 
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factor of ‘income before taxes’ had a large number of categories and certain categories had too 
few respondents; therefore, the significance of the association may be due to chance (Figures 2a 
and 2b).  
 
A significant association was also discovered between consent for residual identifiable clinical 
samples and the hospital at which the participants were currently being seen (Pearson chi-
square=10.433; df=2; p=0.005). Grey’s Hospital had significantly more participants who were 
unsure if they would require ‘consent for research on residual identifiable clinical samples’, 
compared to Edendale Hospital participants. The effect size of this association was considered to 
be moderate and significant (Cramer’s V=0.228; p= 0.005) (Figures 3a and 3b).  
 
When clinically derived samples were unidentifiable, 53.5% of participants felt that consent was 
not necessary; 37.5% felt that it was still necessary; and 9% were unsure. A significant 
association was observed between consent for clinically derived unidentifiable samples and 
current employment (Likelihood Ratio=20.058; df=10; p=0.029). Self-employed participants 
were less likely to require consent for residual unidentifiable clinical samples. The effect size of 
this association was moderate but not significant (Cramer’s V=0.207: p=0.070) (Figures 4a and 
4b). A significant association was also observed between clinically derived unidentifiable 
samples and income before taxes (Likelihood Ratio= 34.102; df=20; p=0.025). Participants who 
earned between R12801 to R 25600 and those that earned over R 25601 were less likely to 
require consent for use of their residual unidentifiable clinical samples. The effect size of this 
association was moderately strong but not significant (Cramer’s V=0274; p=0.071) (Figures 5a 
and 5b).  
 
A significant association was also observed between clinically derived unidentifiable samples 
and the last time participants had tests done using their biological samples (Likelihood 
Ratio=13.970; df=6; p=0.030). Participants who had tests involving their samples less than six 
months ago were more likely to require consent for the use of their residual unidentifiable 
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clinical samples. The effect size of this association was weak but significant (Cramer’s V=0.199; 
p=0.034) (Figures 6a and 6b).  
 
A significant association was also observed between consent for residual unidentifiable clinical 
samples and whether participants had discussions after the test using their samples (Likelihood 
Ratio=6.245; df=2; p=0.044). Participants who did not partake in a discussion after the test were 
less likely to require consent for their residual unidentifiable clinical samples. The effect size of 
this association was weak but significant (Cramer’s V=0.188; p=0.048) (Figures 7a and 7b). 
 
6.4.2 Consent and residual research samples - identifiable and unidentifiable 
Most participants felt that it was necessary to obtain consent for research on residual research 
samples which were identifiable (63.0%), while 27.5% of participants felt that it was not 
necessary, and 9.5% of participants were unsure. A significant association was observed between 
consent for residual identifiable research sample and the hospital at which the participants were 
currently being seen (Pearson chi-square=7.943; df=2; p=0.019). Grey’s Hospital had 
significantly more participants who were unsure as to whether consent was required on residual 
identifiable research samples. The effect size of this association was weak but significant 
(Cramer’s V= 0.199; p= 0.019) (Figures 8a and 8b). Income before taxes also showed a 
significant association showing that participants with an income over R 25601 were more likely 
to be unsure as to whether consent was required on residual identifiable research samples. 
However, as noted before, some categories had too few respondents; therefore, the significance 
of the association is questionable. 
 
When research-derived samples were unidentifiable, 51.5% of participants felt consent was not 
necessary, while 37.5% felt that it was necessary, and 11.0% were unsure. A significant 
association was also observed between consent for residual unidentifiable research sample and 
the hospital at which the participants were currently being seen (Pearson chi-square=6.425; df=2; 
p=0.040). Grey’s Hospital had significantly more participants who were unsure as to whether 
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consent was required for research on residual unidentifiable research samples. The effect size of 
this association was weak but significant (Cramer’s V=0.179; p=0.040) (Figures 9a and 9b).  
 
A significant association was also observed between consent for residual unidentifiable research 
sample and whether participants had discussions after the test using their biological samples 
(Likelihood Ratio=7.868; df=2; p=0.020). Participants who did not partake in a discussion after 
the test using their samples were less likely to require consent for their residual unidentifiable 
research samples. The effect size of this association was weak but significant (Cramer’s V= 
0.209; p=0.023) (Figures 10a and 10b). Current employment and income were also observed to 
have significant associations. With regard to current employment, 100% of self-employed 
participants felt that consent was not necessary for research on residual unidentifiable research 
samples. While this was a moderately strong association it must be noted that this 100% of self-
employed participants only represented 1% of the total sample. In terms of income before taxes, 
individuals who earned between R 12801 to R 25600 were more likely to not require consent 
while individuals who earned over R 25601 were more likely to be unsure. This was a strong and 
significant association even though percentage of the sample was 2% for individuals who earned 




6.4.3 Consent for research studying a disease other than what the sample was initially 
collected for - identifiable and unidentifiable 
With regard to consent for research studying a disease other than what the sample was collected 
for using identifiable human biological samples, 70% of participants felt that consent was 
necessary, while 22% felt that it was unnecessary, and 8% were unsure. No significant 
associations were found between this variable and any of the socio-demographic variables or any 




Given the same scenario but with unidentifiable samples, 54.5% of participants felt that consent 
was not required, while 34.5% felt that it was necessary, and 11% were unsure. A significant 
association was observed between consent for research studying a disease other than what the 
sample was initially collected for using unidentifiable human biological samples and personal 
health (Likelihood Ratio=15.693; df=8; p=0.047). Participants with excellent health were less 
likely to require consent and those with poor health were more likely to require consent. The 
effect size of this association was moderate and significant (Cramer’s V=0.2; p=0.043) (Figures 
11a and 11b).  
 
A significant association was also observed between consent for research studying a disease 
other than what the sample was collected for using unidentifiable human biological samples and 
the hospital at which the participants were currently being seen (Pearson chi-square=11.751; df= 
2; p= 0.003). Grey’s Hospital had significantly more participants who were unsure as to whether 
consent was required for research studying a disease other than what the sample was initially 
collected for using unidentifiable samples. The effect size of this association was moderate and 
significant (Cramer’s V=0.242; p= 0.003) (Figures 12a and 12b).  
 
A significant association was also seen between consent for research studying a disease other 
than what the sample was collected for using unidentifiable human biological samples and the 
last time participants had tests using their biological samples (Likelihood Ratio=13.712; df=6; 
p=0.033). Participants who had tests done less than six months ago were more likely to require 
consent for research studying a disease other than what the sample was collected for using 
unidentifiable human biological samples. The effect size of this association was moderate and 
significant (Cramer’s V=0.201; p=0.031) (Figures 13a and 13b). Income before taxes was also 
observed as having a strong and significant association and participants earning between R 
12801 and R 25601 and those earning R 25601 and over were least likely to require consent for 
research studying a different disease other than what the samples were initially collected for were 




6.4.4 When should consent be obtained and by whom? Is one-time general consent 
sufficient or should individuals be able to provide limits to the use of their samples? 
When asked about when they felt it was appropriate to obtain consent for future research on 
residual clinical samples, a small majority of participants (55.5%) suggested that consent be 
obtained when samples are initially collected. This was followed by 25.0% who believed that it 
was necessary each time a new study was proposed, and 15% who were unsure. A significant 
association was observed between when to obtain consent for future research and personal health 
(Likelihood Ratio=34.418; df=12; p=0.001). Participants with poor (4.5%) and excellent health 
(9.0%) were the least likely to agree that consent be obtained when samples were initially 
collected. The effect size of this association was moderately strong and significant (Cramer’s 
V=0.24; p=0.001) (Figures 14a and 14b). 
 
A significant association was also observed between when to obtain consent for future research 
and the hospital at which the participants were currently being seen (Likelihood Ratio=15.113; 
df=3; p=0.002). Participants at Grey’s Hospital were more likely to be unsure as to when samples 
should be obtained. The effect size of this association was moderately strong and significant 
(Cramer’s V=0.270; p=0.002) (Figures 15a and 15b). Income before tax also showed a 
moderately strong and significant association as 100% of participants who earned a salary over R 
25601 were unsure as to when it was necessary to obtain consent. It should be noted however 
that this 100% only represents 0, 5% of the sample.   
 
When asked who was responsible for obtaining consent, 45% felt that it was the duty of the 
researcher or clinician for whom the samples were initially collected, while 24.5% of participants 
were unsure, 21.5% felt that it was the duty of the researcher who intended to use the samples; 
8.5% felt that it was the duty of the doctor or nurse to obtain consent, and 0.5% felt that it was 
the duty of the laboratories to obtain consent. No significant associations were found between 





With regard to one-time general consent, 53.0% of participants felt that it was sufficient, while 
28.0% felt that it was not sufficient, and 17.5% were unsure. No significant associations were 
found between this variable and any of the socio-demographic variables or any of the clinical 
experience variables. 
 
Half (50%) of participants felt that it is necessary to provide limits to the use of their biological 
samples, while 28.5% felt that it was not necessary, and 18.5% of participants were unsure. A 
small group (3%) of participants chose the ‘other’ option; however, no further explanations were 
provided in the comments line after this question. A significant association was observed 
between providing limits to the use of one’s samples and religion (Likelihood Ratio=35.254; 
df=21; p=0.026). Hindu participants were found to be the most likely to require limits on the use 
of their samples while non-religious individuals were the least likely to require limits on the use 
of their samples. The effect size of this association was moderate but not significant (Cramer’s 
V=0.227; p=0.073) (Figures 16a and 16b).  
 
A significant association was also observed between providing limits to the use of one’s samples 
and how religious an individual was (Likelihood Ratio=28.978; df=9; p=0.001). Participants who 
were not religious at all (5%) were least likely to require that limits be imposed to the use of their 
samples. The effect size of this association was moderate and significant (Cramer’s V=0.223; 
p=0.000) (Figures 17a and 17b). 
 
6.5 Desirability of receiving clinically significant results 
According to the Department of Health (2015) it is the ethical obligation of researchers to 
maximize benefits and seek to improve the human condition in research involving human 
participants. Research with human participants is not only beneficial to the researchers and the 
public, but also to individual donors who may too benefit from the results (Simitis, 2004). It is 
thus the responsibility of researchers to inform participants and the study community of the 
results of the research in a language which they are able to understand, and in a format that is 
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relevant and appropriate (Emanuel et al., 2000; Emanuel et al., 2004; Wassenaar, 2006). 
Frequency of responses on Table 4. 
 
When questioned as to whether they would like to be informed about clinically significant 
results, 88.0% of participants said yes, 8.0% said no, and 4.0% were unsure. A significant 
association was observed between desirability of being informed about clinically significant 
results and whether participants received a discussion after the test using their biological samples 
(Likelihood Ratio=7.502; df=2; p= 023). The effect size of this association was weak and not 
significant (Cramer’s V=0.162; p= 0.106) (Figures 18a and 18b). 
 
When they were asked if they would want the researcher to inform the doctor about these 
clinically significant results, 76.0% of participants said yes, 17.5% said no, and 6.5% were 
unsure. A significant association was observed between the desirability of informing the doctor 
of results of clinical significance and sex (Likelihood Ratio=7.167; df=2; p=0.028). Female 
participants were more likely than males to want their doctors to be informed of results of 
clinical significance. The effect size of this association was weak but significant (Cramer’s 
V=0.192; p=0.025) (Figures 19a and 19b).  
 
A significant association was also observed between the desirability of informing the doctor of 
results of clinical significance and level of education (Likelihood Ratio=21.371; df=12; 
p=0.045). Participants with higher certificates, diplomas and bachelor’s degrees were more likely 
to want their doctors to be informed of their results. The effect size of this association was 
moderate and significant (Cramer’s V=0.248; p=0.017) (Figures 20a and 20b).  
 
A significant association was also observed between the desirability of informing the doctor of 
results of clinical significance and one’s personal health (Likelihood Ratio=21. 090; df=8; 
p=0.007). Participants with poor health were more likely to want their doctors to be informed of 
results of clinical significance. The effect size of this association was moderate and significant 




A significant association was also observed between the desirability of informing the doctor of 
results of clinical significance and whether participants had ever had tests done using their 
biological samples (Likelihood Ratio=6.421; df=2; p=0.040). Participants who had previous tests 
done using their biological samples were more likely to want their doctors to be informed of 
results of clinical significance. The effect size of this association was weak but significant 
(Cramer’s V=0.190; p=0.027) (Figures 22a and 22b). 
  
6.6 Confidentiality 
When pursuing their scientific aims, researchers need to ensure that the rights and dignity of their 
participants are protected throughout the duration of study (National Bioethics Advisory 
Committee, 1999). Part of this protection includes protection from non-physical risks such as 
divulging of personal information (National Bioethics Advisory Committee, 1999). When 
dealing with human biological samples it is important for researchers to realise that these 
samples contain personal information about individuals and they need take all necessary 
measures to ensure that participants’ rights to confidentiality are respected (National Bioethics 
Advisory Committee, 1999).  Ensuring protection becomes increasingly difficult with research 
on stored samples because these are usually stored over long periods of time for unknown future 
research (National Bioethics Advisory Committee, 1999). It is thus the duty of researchers, 
RECs, policies and legislation to guide the process of research on stored biological samples. 
These need to be informed by systematic assessments of public opinion. 
 
To gain perspective on perceptions of confidentiality, participants were given an example of 
three types of sensitive personal information, namely medical information, credit history 
information, and employment history information. They were then asked which of the three 
types of the aforementioned sensitive personal information was most likely to be misused (Table 
5). Over half (55.0%) said medical information, 26.5% were unsure, 11.0% said employment 
history information, and 7.5% said credit history information. A significant association was 
observed between the confidential information that was most likely to be misused and religion 
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group (Likelihood Ratio=33.912; df=21; p=0.037). All Hindu respondents (100%) and 83.3% of 
Muslim respondents felt that medical information was the most likely to be misused. It is worth 
noting that these categories had very few participants so this association could possibly be due to 
chance. The effect size of this association was moderate but not significant (Cramer’s V=0.226; 
p=0.079) (Figures 23a and 23b).  
 
Although not one of the research aims or questions, a significant association was observed 
between the confidential information that was most likely to be misused and the hospital at 
which the participants was currently being seen (Pearson chi-square=22.996; df=3; p=0.000). 
Participants at Edendale Hospital felt that medical information was the most likely to be 
misused, while participants at Grey’s Hospital felt that employment information was the most 
likely to be misused. The effect size of this association was very strong and significant (Cramer’s 
V=0.339; p=0.000) (Figures 24a and 24b). When asked about which type of information was 
least likely to be misused, 37.0% said employment history information, 34.5% were unsure, 
14.5% said medical information, and 14.0% said credit history information. A significant 
association was observed between the confidential information that was least likely to be 
misused and the hospital at which the participant was currently being seen (Pearson chi-
square=9.386; df=3; p=0.025). Participants at Grey’s Hospital felt that medical information was 
least likely to be misused. The effect size of this association was moderate and significant 
(Cramer’s V=0.217; p=0.025) (Figures 25a and 25b). 
 
Participants were then asked about the risk of moving from records written on paper to 
computerised records, with regard to the possibility of violation of confidentiality. Just under 
half (44.0%) of participants felt that moving to computerised records decreases the risk of 
violation of confidentiality, while 26.5% felt that it does not change the risk, 15.5% felt that it 
increases the risk, and 14.5% were unsure. No significant associations were found between this 




When questioned as to whether the confidentiality of their medical records had ever been 
violated, 80% of participants said they had not, 11.5% said they were unsure, and 8.5% said they 
had. A further probing qualitative question revealed that confidentiality had been violated when 
nurses disclosed to family members without consent and when contents of the participant’s 
records were discussed in spaces where other people could hear. 
 
 Participants were then asked if they had ever avoided seeking physical or mental help out of 
concerns about confidentiality; a large majority (78.5%) said no, while 21.5% said yes.  
 
Avoiding seeking physical or mental health out of concerns about confidentiality had moderately 
significant associations with how religious a person is; level of education; and current 
employment. With reference to how religious a person was, participants who were not religious 
at all were least likely to avoid seeking help because of concerns about confidentiality. With 
regard to level of education, participants with a higher certificate and those with a bachelor’s 
degree were also the least likely to avoid seeking help because of confidentiality concerns. None 
of the self-employed participants had avoided help out of concerns about  confidentiality, but it 
must be noted that there were only two respondents in this category thus the generalizability of 
this is questionable. 
 
Personal health also showed a very strong association. Participants with poor health were more 
likely to avoid seeking medical help because of concerns about confidentiality. 
 
Participants were then given an example of four types of medical information, namely genetic 
information, laboratory test information, doctor’s notes from visits, and mental health 
information. Of these four types of medical information, participants were asked which type was 
most sensitive. A third (31.5%) said they were all equally important, 22.0% said doctor’s notes 
from visits, 21.5% said laboratory test information, 10.5% said genetic information, and 10.5% 
said that they were unsure. Significant associations were observed with religion, level of 
education, current employment status, and personal health, the hospital where participants were 
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currently being seen, and whether they had previously had tests done using their biological 
samples. The effect sizes of religion and personal health were not significant. Level of education 
and current employment were both moderately significant factors and participants who are self-
employed and those who had bachelor’s degrees felt that notes from doctor visits were most 
likely to be misused. Hospital had a very significant association and Grey’s had significantly 
more participants who were unsure as to which type of medical information was most sensitive.  
 
6.7 Summary of results 
 
The main aim of the study was to quantitatively explore public attitudes to the collection and 
storage of human biological samples through cross-sectional surveys conducted at Greys and 
Edendale Hospitals. The main questions that the researcher was interested in were 1) whether 
individuals from whom stored biological samples were obtained think that their consent should 
be required? 2) would the like to receive results of clinical significance? 3)  what are people’s 
perceptions of confidentiality? The researcher was also interested in whether any significant 
associations existed between any of these factors and the socio-demographic factors and the 
previous clinical experience factors. For the purpose of this summary only associations that have 
a significant effect size will be reported. As stated in most parts of this research, some of the 
independent variable questions have several so the generalizability of the results must be viewed 
with caution. These factors variables include current employment, income before taxes, level of 
education and religion. This will be addressed again in section 8.1. Limitations.  
 
The findings show that more than half of participants believed that their consent was necessary for 
future research on stored biological samples. When samples were identifiable 54% ≥ of 
participants thought consent was necessary and for unidentifiable samples the percentages range 
from 63% ≤ 70.5% Participants were more likely to require consent for clinically derived samples 
and for research studying diseases other than what their samples were taken for. Factors that were 
observed as having a significant association with participants who believed that consent was 
necessary included current employment, income before taxes, personal health and whether an 
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individual had previously had tests run using their samples. The effect size of these associations 
ranged from moderately strong to strong.  
The study suggested that participants most likely to require consent for future research included 
students, self-employed participants, those earning salaries between R 12801- R 25600, those with 
excellent personal health and those who had had tests (using biological samples) run in the last 6 
months. Participants that were least likely to require consent for future research included those 
with poor health; those who had tests using their biological samples run  in the last 6 months, and 
those who earned R 12 801- R 25600 and over; and those who had no post-test discussion after 
they previously had a test run using their biological samples. Participants that were more likely to 
be unsure were those who earned a salary over R 25601 and those who were currently being seen 
at Grey’s Hospital. 
The were some contradictions with some of the factors, such as participants who earned between 
R 12 801- R 25600 and participants who had tests run in the past 6 months These differences were 
due to participants responding differently in the different consent scenarios of clinically derived 
samples, research derived samples and consent for studying a different disease other than what the 
samples were collected for. It is also worth considering that the difference regarding income 
applied to very few respondents.  
With regard to when participants felt that it was necessary to obtain consent for future research,  
over half of the participants believed that it ought to be obtained when samples were initially 
collected. Participants who rated their personal health as poor or excellent were less likely to agree 
to this. Participants who earned a salary over R 25601 and those from Grey’s Hospital were most 
likely to be unsure. 
The results show that a little under half of the participants felt that obtaining consent for future 
research was the responsibility of the initial clinician or researcher while 53% believed that one-
time general consent was sufficient. No significant associations were observed with these and any 
of the socio-demographic factors or clinical experience factors. With regard to providing limits to 
 
 72 
the use of one’s samples- 53% of participants felt that it was necessary to set limits. Participants 
that were not religious were more likely to think that it is not necessary. 
Most participants expressed a wish to know about their results on samples taken for research 
purposes, especially for results of clinical significance (88%) and they would like their doctors to 
be informed of these results. Participants that were more likely to want their doctors to be 
informed of clinically significant results were females, those with poor health, those who had had 
previous tests using biological samples, those with a higher certificate, diploma and a bachelor’s 
degree.  
With regard to different types of confidential information - medical information was regarded as 
the most sensitive and the most likely to be misused. Participants from Edendale Hospital were 
more likely to agree to this while participants at Grey’s Hospital saw it as the least likely to be 
misused. Participants at Grey were more likely to believe that employment information was the 
most likely to be misused. 
Finally with regard to medical information, a little less than half of participants felt that moving 
from paper records to computerized records would decrease the chances of violation of medical 
records. Most participants (80%) reported to have never had the confidentiality of their medical 
records violated and the majority (70%) had never avoided seeking medical help in fear of their 
confidentiality being violated. A third of participants felt that all types of medical information 
were equally important. However, those with bachelor’s degrees and those who were self-
employed were most likely to think that notes from doctors’ visits were the most important. 
 
Chapter 7: Discussion 
This chapter will discuss the findings/results of this research in light of the literature presented in 
previous chapters regarding ethics in biomedical research.  The South African context will also 
be taken into consideration when discussing the results. This section will start by discussing 
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participant socio-demographics and previous clinical experience, which are the independent 
variables. It will be followed by a discussion of the research questions (dependent variables). 
 
7.1 Participant socio-demographics and previous clinical experience 
 
Participant socio-demographics showed that most participants were Black and that there were 
significantly more females than males. The researcher attributes this to two factors: firstly, in 
South Africa the majority of the population is Black; therefore, the fact that they are the most 
represented in this sample is justifiable. The discrepancy between the genders can be explained 
by the fact that, when it comes to help-seeking behaviour, women are more likely than men to 
seek help for problems from health professionals (Oliver, Pearson, Coe & Gunnel, 2005). This 
means that a higher representation by women in this sample is also justifiable in relation to the 
population of help-seekers.  
 
With regard to previous clinical experience, most participants had previously had tests done 
using their biological samples and most of these tests had been done within the past two years. 
Most participants had been engaged in discussions by healthcare professionals both before and 
after the tests were done, and these discussions were mostly satisfactory. Most participants were 
aware that tests using their biological samples were optional. Discussions about the possibility of 
future research on residual human biological samples were mostly not done within the hospitals. 
The possible reason behind the lack of these discussions is that in South Africa clinically 
obtained samples are not routinely retained for future research purposes yet.  
 
7.2 Do individuals from whom stored biological samples were obtained think their consent 
should be required for future research? 
 
When discussing the topic of research on stored biological samples one of the main issues that 
arise is that of consent. Debates over consent for research on stored biological samples revolve 
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around questions of: (1) whether it is necessary for research on stored biological samples (2) 
when it should be obtained (3) who should be responsible for obtaining it (4) whether one-time 
general consent is sufficient (5) whether individuals should be allowed to provide limits to the 
use of their samples. While ethical guidelines that govern the use of human biological samples 
are available in South Africa as published by the Department of Health (and entities such as the 
Health Professions Council of South Africa and the South African Medical Research Council), 
relatively little has been published with regard to public attitudes to the use of their samples. In 
addition to legal and ethical principles, public attitudes should inform guideline development to 
ensure that they are in line with individual beliefs and values. 
 
Findings in this study show that more than half of participants required consent for all research 
on stored biological samples. Participants were stricter about consent requirements when samples 
were identifiable, when they were clinically derived and when the samples will be used to study 
a different disease other than what they were initially collected for. Notable differences and 
minor similarities were evident between this study and the original study which it is based on. 
Wendler and Emanuel (2002) also found that respondents were more likely to require consent 
when samples were clinically derived and identifiable. The difference that was noted between 
this study and the original study was that in the original study participants were far less likely to 
require consent for research derived samples and for research studying diseases other than what 
the sample was collected for. Even when samples were identifiable, less than a third of the 
respondents felt that consent was necessary. While the original study found that no significant 
associations existed between consent and any of the socio-demographic and clinical experience 
variables; the current study observed that students, self-employed participants, those earning 
between R12 801 to R25 600, those with excellent health and those who had had tests using 
biological samples run less than 6 months ago were more likely to require consent. Previous 
studies support that previous clinical experience and health status have significant associations 
with willingness to donate (Al-Jumah et al., 2011; Bussey-Jones et al., 2010). Participants with 
excellent health are possibly more likely to require consent as compared with those with poor 
health because they because they are in less need of sophisticated medical interventions whereas 
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poor people would be more open to these for the sake of their health. Current employment 
(students and self-employed) and income were not found to be significant by any of the literature 
presented. The researcher attributes the associations of these variables in this study as possibly 
due to chance judging from the very few respondents in these categories. 
 
An observation that was made comparing these two studies was that participants in the current 
study were more likely to require consent as opposed to those in the original study. The original 
study claimed that participants were less likely to require future consent for research derived 
samples as it had previously been obtained (Wendler & Emanuel, 2002). It also claimed that 
respondents view future consent for further research on research derived samples as 
‘unnecessary’; and it suggests that if participants could be given the opportunity to consent for 
their clinically derived samples to be used for research purposes then they can be treated as 
research samples (Wendler & Emanuel, 2002). 
 
The original study made the assumption that because respondents were less likely to require 
consent for research derived samples and for research studying diseases other that they were 
collected for, it suggested that individuals did not feel the need to provide limits to the use of 
their samples and that broad consent applied. The current study chose to investigate this 
assumption by adding questions that addressed when participants thought it was necessary to 
obtain consent, and which consent model they preferred. The present findings showed that while 
almost one third of participants supported the idea of future consent being obtained when 
samples were initially collected,  an almost equal split was seen between participants who felt 
that one-time general consent was enough and those who felt that it was necessary to set limits 
on the future use of their samples. Non-religious participants were less likely to require that 
limits be imposed on their samples. The reason for this could be because they are less likely to 
have religious views which may include beliefs about science and genetic discovery (Al- Jumah 




This data suggests that individuals need to be provided with the opportunity to consent for any 
future research using their stored biological samples. Should the task of re-contacting individuals 
for further consent be costly and difficult, then it is the responsibility of the initial researcher or 
clinician to obtain this consent (Bauman et al., 2003). The findings also suggest that individuals 
need to be given the option to either provide broad consent or provide consent with limits to 
certain diseases/illnesses. Department of Health guidance (2015) states that in the absence of 
broad consent where samples are anonymous, unidentifiable, and where the results would not 
cause any harm to participants, the need for re-consent can be waived by a registered REC. Re-
consent for research on stored samples may only be necessary if future research is studying a 
disease other than what it was initially collected for or if there is a way of linking identifying 
details to samples (Department of Health, 2015). While some of these guidelines allow for a 
waiver of re-consent, the fact that over half of the participants felt that future consent was 
necessary in all scenarios of research on biological samples should be considered. Researchers 
and RECs need to consider what participants regard as ‘causing harm’ and assess whether the 
use of samples without consent could be classified as such – or as a possible harm to dignity, if 
not to body. While it is important for researchers to respect individuals as autonomous persons 
by allowing them control over the use of their samples; re-contacting individuals (in the absence 
of future consent) can be regarded as an invasion of privacy (Chen et al., 2005; Simitis, 2004). 
Previous literature further suggests that initial clinicians and researchers should provide 
individuals a checklist of options from which they can choose the research they approve or 
disapprove of regarding their samples (Porter et al., 2000; Chen et al., 2005).This again 
highlights the need for South African guidelines to consider requiring a process of obtaining 
consent for future use.  
 
Another noteworthy finding that was made was that for most questions pertaining to consent, 
participants from Grey’s Hospital were more likely to respond ‘unsure ‘as compared to 
participants from Edendale Hospital. This could be because Grey’s is a referral hospital (patients 
referred from other hospitals or clinics) while Edendale is more of a self-referral hospital. This 
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7.3 Do participants want to receive results of clinical significance? 
 
Findings showed that most participants wanted to be informed of results of clinical significance. 
No significant associations were found between this variable and any other variables. 
Participants also wanted their doctor to be informed of results of clinical significance, especially 
females, and those with a higher certificate, diploma and bachelor’s degree. These results echo 
those found in previous literature (Abou-Zeid et al., 2010; Halverson & Friedman Ross, 2012; 
Hoeyer et al., 2004; Opinion Leader, 2012; Wendler & Emanuel, 2002). According to Hoeyer et 
al. (2004) and Opinion Leader (2012), participants wanted to be informed of results of clinical 
significance, especially if these suggested susceptibility to contracting a disease that could be 
preventable by early detection.  The reason that participants would want their doctors to be 
informed of clinically significant results is likely because they would need their doctors’ support 
in treating or managing the condition detected. The fact that females were more likely to want 
their doctors informed of their results again highlights the point of how they are more likely to 
seek help more than men (Oliver et al., 2005). 
 
Informing participants of results of clinical significance can be regarded as an important part in 
benefit sharing. However it poses a challenge to researchers especially if samples are 
unidentifiable. Even with identifiable details it could be difficult /impossible tracking down 
participants because of distance, time and possibly death (Bauman et al., 2003). In light of the 
findings of the current research and of applicable ethics guidance, it would seem like in order to 
facilitate this process of disseminating clinically significant results the researcher/clinician who 
collected the initial sample and the researcher who uses the stored sample should work 
collaboratively. The initial researcher/clinician would have to include in their consent form 
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provisions for future research and give participants the option of obtaining significant results. 
The initial researcher would also have to code these samples and provide the researcher with 
coded samples. Databases would have to be created and a decision could be made for either the 
researcher to relay significant results to the initial clinician/researcher to inform participants; or 
participants could be given the option to contact the initial/clinician or researcher to find out. 
 
 
7.4. What are participants’ perceptions of confidentiality? 
Findings show that medical information was regarded as the most important type of confidential 
information especially for participants who were currently being seen at Edendale Hospital. Most 
participants reported that the confidentiality of their medical records had never been violated and 
they had never avoided seeking medical assistance out of fear of their confidentiality being 
violated. Approximately half of the participants felt that moving from paper records to 
computerized records decreased the likelihood of their confidentiality being violated. These 
findings suggest that participants have trust in their clinician’s ability to protect confidential 
information. Public trust is important as individuals are more likely to provide future consent for 
the use of their clinical samples if they have faith that clinicians will protect their samples 
(Baumen et al., 2003; Kettis-Linblad et al., 2004; Simitis, 2004). 
 
In order to start the process of requesting future consent for clinical samples, it is important for 
clinicians to maintain this trust by engaging in open and honest dialogues about confidentiality 
with participants. Clinicians need to make clear if samples are intended for future use and they 
need to obtain consent and find a way to disseminate results of clinical significance to 
individuals. Hospitals provide a convenient source of biological samples but it is not enough to 
assume that they can freely be used at researchers’ discretion. This should be considered when 






Chapter 8: Limitations, conclusions and recommendations 
 
8.1 Limitations 
Several possible limitations of this study can be noted. Firstly, the initial proposal intended for 
fifty participants to be recruited from each of the three major government hospitals in 
Pietermaritzburg (Edendale Hospital, Grey’s Hospital, Northdale Hospital). However permission 
was not obtained from Northdale Hospital. As a result of this the researcher took the decision to 
use only two hospitals and the increase the sample size to one hundred participants from each 
hospital. 
Secondly, certain variables such as current employment, income, religion and level of education 
had too many categories and some of these categories had too few respondents. This limits 
generalizability as some significant association may have been purely due to chance as opposed 
to statistical significance, Thirdly, since the subject of research on stored samples was a fairly 
new concept to participants it possibly meant that they had little to no understanding about the 
potential benefits or harms associated with it. Responses thus could have been due to a 
misunderstanding. Fourthly, since participants were currently seeking help at hospitals one 
cannot be sure how the nature of their illness affected their cognitive abilities and emotional state 
whilst completing the survey, although the researcher (a psychology intern) took care to avoid 
those in obvious distress or incompetent. The last limitation was due to the fact that the 
researcher only asked questions about identifiable and unidentifiable samples and failed to ask 
about coded samples. The interest in coded samples is that they could affect participants’ 
(un)willingness to participate. Finally, the survey focused too much on issues surrounding 
consent only and did not do justice on desirability of clinically significant results and perceptions 
of confidentiality. Part of this was because the original survey was structured this way; however 







The main aim of this research was to quantitatively explore public attitudes the collection and 
storage of their human biological samples. To gain perspective of the public, the researcher used 
three questions. The first question sought to find whether individuals thought consent was 
necessary for research on their stored biological samples. Stored biological samples for the 
purpose of this question were classified as identifiable or unidentifiable; and they were further 
classified as clinically derived, research derived, and those used to study a different disease other 
than what they were collected for. In general, the findings of this research show that consent was 
regarded as always necessary for more than half of the participants when a study research is 
proposed on their stored samples, regardless of whether they were identifiable/unidentifiable 
clinically/research derived or were being used to study a different disease. Participants were 
however more likely to require consent for clinically derived samples and for research studying a 
different disease other than what they were collected for. Individuals who had excellent health 
and those who had previous tests using their biological samples were also more likely to require 
consent. 
 
 The second question asked whether individuals wanted to be informed of results of clinical 
significance after research had been conducted on their stored samples. Most participants wanted 
to be informed of clinically significant results and they also wanted researchers to inform their 
doctor. Females were more likely than males to want their doctors to be informed. 
 
Lastly, the research sought to explore individuals’ perceptions of confidentiality. From the 
findings it was deduced that individuals had a positive perception of the protection of their 
confidentiality at medical facilities. Most participants reported that there had never been any 
breach of confidentiality of their medical records and they had never avoided seeking help out of 
concerns of confidentiality. Participants saw the move from paper to computerized records as a 







 Research on stored biological samples was a fairly new concept to participants, 
suggesting that there is a need for public knowledge on this subject. Researchers need to 
find a way of making this knowledge available to the general public in a way that is 
simple to understand for most. A possible way of doing this would be via posters in 
hospital waiting areas and pamphlets throughout hospitals. These would have to be in a 
various languages to accommodate everyone. Creating this awareness is the first step in 
encouraging participants to make informed decisions about research on their stored 
samples 
 It is also suggested that clinicians/researchers need to start engaging with issues around 
research on stored biological samples with their patients/participants. Biomedical 
research is not only beneficial to researchers but it is beneficial to the general public as 
well. Information needs to trickle down to ground level in order to achieve public support 
 Future researchers on this topic need to consider a qualitative approach in order to gain a 
deeper insight into the views expressed in this study. This qualitative research could be 
done with individual participants or with focus groups Further researchers on this topic 
also need to consider focusing on only one concept at a time (e.g., confidentiality only) so 
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Appendix F:  English information sheet and consent form 
 




Information Sheet and Consent to Participate in Research Entitled: Collection, storage and use of 
biological samples for future research: A cross-sectional study of opinions of 
Pietermaritzburg government hospital out-patients.   
 
 
12 November 2015  
 
Dear Sir/ Madam 
 
My name is Nonhlanhla Keswa from the University of KwaZulu-Natal. I am currently pursuing my 
Master’s Degree in Educational Psychology, and in partial fulfilment of this, I am required to conduct a 
research study. Should you wish to contact me, you may do so on 082 666 8118 or alternatively you may 
email me on missk3003@gmail.com .  
 
You are being invited to participate in a research study that seeks to determine the attitudes of 
Pietermaritzburg government hospital out-patients to the collection and storage of human biological 
samples for future research purposes. The aim of this study is to determine how people feel about the 
collection, use and storage of their human biological samples (e.g.: blood, urine, tissue) for future 
research purposes. The study is expected to enrol a minimum of 50 participants from each of the local 
government hospitals, namely; Edendale Hospital, Northdale Hospital and Grey’s Hospital. Participation 
in this study involves completing a questionnaire which will take approximately 10 minutes of your 
time. Should you wish to find out more about the collection and storage of biological samples for future 
research purposes before or after you complete questionnaire, all questions will be kindly answered. 
Information obtained from this questionnaire will remain entirely anonymous as you will not be required 
to provide your name or any identifiable details on your answer sheet. Instead your form will be coded 
into a number.  
 
Your participation in this study does not involve any physical risk or emotional risk to you. There will be 
no direct benefit to you by your participation in this research study. Scientifically, this study hopes to 
lead to a better understanding of people’s attitudes to the use of their human biological samples as this 
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could lead to more measures being taken when requesting consent from patients/participants for the use 
of their samples for research purposes. 
 
This study has been ethically reviewed and approved by the University of KwaZulu-Natal Biomedical 
Research Ethics Committee (approval number: BE 232/15). 
 
In the event of any problems or concerns/questions you may contact the researcher at (082 6668118 or 
missk3003@gmail.com) or my supervisor Prof D Wassenaar (Wassenaar@ukzn.ac.za  Ph 033-
2605853), or the UKZN Biomedical Research Ethics Committee, contact details as follows:  
 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
 
Participation in this study is completely voluntary, and you are free to withdraw at any stage. In the 
event of refusal or withdrawal of participation, you will not incur penalty or loss of treatment or any 
other benefit to which you are normally entitled to. Should you wish to withdraw, you will be required to 
inform the researcher. Upon withdrawal, you may choose whether previously obtained information may 
be used or whether it should be discarded.  
 
No costs will be incurred by participants as a result of participation in the study, and there are no 
incentives or reimbursements for participation in the study. 
 
Information obtained from this questionnaire will remain entirely anonymous as you will not be required 
to provide your name or any identifiable details on your questionnaire, and your informed consent form 
will be stored independent from your questionnaire. Your questionnaire will be coded with a number 
which cannot be linked back to you. The results of this research could be presented at a post-graduate 
conference which is hosted at the University of KwaZulu-Natal; or they could be published, but as 
mentioned above your identity will remain fully anonymous. A final copy of this study can be accessed 













I (Name ____________________________________________) have been informed about the study 
entitled “Collection, storage and use of blood samples for future research: views of Pietermaritzburg 
government hospital out-patients as expressed in a cross-sectional survey ” by Nonhlanhla Keswa 
 
  
 I understand the purpose and procedures of the study. 
 
 I have been given an opportunity to answer questions about the study and have had answers to 
my satisfaction. 
 
 I declare that my participation in this study is entirely voluntary and that I may withdraw at any 
time without affecting any treatment or care that I would usually be entitled to. 
 
 I have been informed about any available compensation or medical treatment if injury occurs to 
me as a result of study-related procedures. 
 
 If I have any further questions/concerns or queries related to the study I understand that I may 
contact the researcher at (provide details). 
 
 If I have any questions or concerns about my rights as a study participant, or if I am concerned 
about an aspect of the study or the researchers then I may contact: 
  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 




____________________      ____________________ 





____________________   _____________________ 
Signature of Witness                                Date 
(Where applicable)      
 
 
____________________   _____________________ 






Appendix G: IsiZulu information sheet and consent form    
 
Ifomu lokuchazeleka kanye nefomu lesivumelwano 
Ifomu lokuchazeleka kanye nefomu lesivumelwano yokuba ingxenye yocwaningo, isihloko: 
Ukuqoqwa kanye nokugcinwa kwama-sampula omzimba ukuze asentshenziswe 
kucwaningoolusesikhathini esizayo: Ucwaningo lobuningi oluhlola imibono yeziguli 
ezingalalisiwe ezibhedlela zikaHhulumeni ePietermaritzburg. 
12 November 2015 
Ngiyakubingelela, 
Igama lami ngingu-Nonhlanhla Keswa owenza izifundo zakhe ze-Masters kwi-Psychology 
eNyuvesi yaKwaZulu-Natali. Ngenza ucwaningo olunesihloko: “Ukuqoqwa kanye nokugcinwa 
kwama-sampula omzimba ukuze asentshenziswe kucwaningoolusesikhathini esizayo: 
Ucwaningo lobuningi oluhlola imibono yeziguli ezingalalisiwe ezibhedlela zikaHhulumeni 
ePietermaritzburg”. Uma ufisa ukuthintana nami ungangithinta kwinombolo ethi 0826668118 




Uyamenywa ukuba ube yingxenye yalolucwaningo. Injongo yalolucwaningo ukuthola ulwazi 
ngokuthi abantu bacabangani ngokuqoqwa kanye nokugcinwa kwamasampula omzimba (igazi, 
umchamo, amathe njalo njalo) ukuze asetshenziswa kucwaningo olusesikhathini esizayo. 
Lolucwaningo kuzoba ucwaningo lobuningi oluzodinga iziguli ezingalalisiwe eziwe-50 kuzo 
zonke izibhedlela zikaHhulumeni  ePietermaritzburg (Grey’s Hospital, Edendale Hospital and 
Northdale Hospital). Ngokuba ingxenye kulolucwaningo ulindeleke ukuba ufake imibono yakho 
ngokuphendula imibuzo, okungathatha imizuzu elishumi. Imibono yakho kulolucwaningo 
iyogcinwa iyimfihlo; igama nesibongo sakho ngeke kwadingeka kwifomu lohlelo lwemibuzo 
yocwaningo. 
Ukuba yingxenye yalolucwaningo angeke kube yingozi kuwena emzimbeni noma emoyeni. 
Akukho okuphathekayo ozokuthola ngokuba ingxenye yalolucwaningo. Ngokolwazi, 
lolucwaningo lufisa ukuthola ulwazi olubanzi ngemibono yabantu mayelana nokusetshenziswa 
kwama-sampula abo ngoba lemibono ibalulekile ukuze kubekwe imithetho nemigomo uma 
kusetshenziswa amasampula abantu. 
Lolocwaningo lunikwe imvume yiBiomedical Research Ethics Committee yase University 
yaKwaZulu-Natal (inombolo yemvume: BE 232/15). 
Uma uba nenkinga noma unemibuzo ungathinta mina umcwaningi (Nonhlanhla Keswa- 
0826668118) noma ungathinta umhloli wami (Professor Douglas Wassenaar- ph 033-2605853/ 
email wassenaar@ukzn.ac.za). Imininingwane yeBiomedical Research Ethics Committee yase 
University yaKwaZulu-Natal: 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 





Ukuba yingxenye yalolucwaningo yinketho yakho, akuphoqelekile. Ukubamba kwakho iqhaza 
kulolucwaningo kumahhala futhi ukungalibambi iqhaza ngeke kukubeke encupheni yokuthola 
usizo lapha esibhedlela. Unelungelo lokukhetha ukuqhubeka noma ukungaqhubeki uma 
usuqalile. Uma ukhetha ukungaqhubeki usuqalile, unelungelo futhi lokukhetha ukuthi imibono 
yakho osuyibhalile ingasetshenziswa noma cha. 
Ukuba yinxenya yalolucwaningo ngeke kwakukhubaza ngokumuphefumulo noma ngayiphi 
enye indlela. Imininingwane ebanzi ngalolucwaningo iyatholakala, unelungelo lokubuza. 
Imiphumela yalolucwaningo ingadingidwa kwinkomfa ezobe ibanjelwe eNyuvesi yaKwaZulu-
Natali ekupheleni konyaka. Eminye yayo ingashicilelwa emabhukwini ahlukene, futhi 
ingatholokala emtapweni wolwazi waseNyuvesi yaKwaZulu-Natali. Isiqiniseko sizothathwa 





Mina _________________     (igama lakho eliphelele), sengifundile futhi nginolwazi 
lwemigomo  yokuba inxenye yalolucwaningo, isihloko: “Ukuqoqwa kanye nokugcinwa 
kwama-sampula omzimba ukuze asentshenziswe kucwaningoolusesikhathini esizayo: 
Ucwaningo lobuningi oluhlola imibono yeziguli ezingalalisiwe ezibhedlela zikaHhulumeni 
ePietermaritzburg” olwenziwa uNonhlanhla Keswa.  
 
 
 Ngichazelekile ngesizathu kanye nohlelo lwalolucwaningo. 
 Nginikeziwe ithuba lokuthi ngibuze imibuzo enginayo ngaze ngagculiseka. 
 Ngiyaqiniseka ukuthi angiphoqiwe ukuthi ngibe yingxenye yalolucwaningo. Ngiyazi 
ukuthi nginelungelo lokukhetha ukuqhubeka noma ukungaqhubeki. 
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 Uma nginemibuzo ngiyazi ukuthi ngingathintana nobani. 
 Uma nginemibuzo noma kukhona engikathazeka ngoko ngalolucwaningo 
ngingathintana ne: 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
 
 
____________________      ____________________ 
I-signature yami                                        Date 
 
 
____________________   _____________________ 
I-signature yafakazi                                Date 
(Where applicable)      
 
 
____________________   _____________________ 







Appendix H: Original Survey 
1. Researchers now have genetic tests that allow them to assess if Alzheimer’s Disease 
runs in families. 
 
Has anyone ever tested your blood or saliva for Alzheimer’s Disease? 





1a. Has anyone offered you a blood or saliva test for Alzheimer’s Disease that you decided 
not to have done? 
1 YES 
2 NO  (SKIP TO 18) 
 




(SKIP TO 18) 
 
 
2. About how long ago were you tested, would you say it was less than 6 months ago, 
between 6 months and a year ago, between 1 and 2 years ago, or more than 2 years ago?  
1 LESS THAN 6 MONTHS AGO 
2 BETWEEN 6 MONTHS AND A YEAR AGO 
3 BETWEEN 1 AND 2 YEARS AGO 
4 MORE THAN 2 YEARS AGO 
 
 
3. Was it the genetic test for Apolipoprotein-E, or APOE for short?  
1 YES   (SKIP TO 4) 
2 NO 
9 DON’T KNOW  (SKIP TO 4) 
 








4. As I ask you about the details of your genetic testing for Alzheimers, I want to reassure 
you that your answers will be kept confidential so that no one outside our research team will 
know what you say. 
Did you receive an explanation or participate in a discussion about the Alzheimer’s test either 
before or at the time you went to receive it? 
1 YES 
2 NO  (SKIP TO 7) 




5. Did you decide to be tested because you were convinced by the explanation or had you 
already decided to be tested before hearing the explanation? 
1 EXPLANATION CONVINCED 
2 ALREADY DECIDED 
9 DON’T KNOW 
 
 
6. Before you were tested for Alzheimer’s Disease, was there anything that was not 
discussed as much as you would have liked? 
1 YES  
2 NO    (SKIP TO 7) 
 






7. Was there a discussion about the Alzheimer’s test at any time after it was performed? 
1 YES 
2  NO   (IF NO TO 4 AND 7, SKIP TO 14) 
 
 
8. Added together, how much time in minutes would you estimate was spent providing you 












9. Who explained or discussed the test with you, was it a doctor, a nurse, a social worker, a 
genetic counselor, or someone else? 
1 A DOCTOR 
2 A NURSE 
3  SOCIAL WORKER 
4 A GENETIC COUNSELOR 
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5 SOMEONE ELSE   (SPECIFY________________________) 
6 COMBINATION    (SPECIFY ________________________) 
9 DONT KNOW 
 
 
10. As part of the information you received, how clearly was it explained that being tested 
for Alzheimer’s Disease was your option, and not a requirement?  Would you say very clearly, 
clearly, not very clearly, or not clearly at all? 
1 VERY CLEARLY 
2 CLEARLY 
3 NOT VERY CLEARLY 
4 NOT CLEARLY AT ALL 
5 WAS NOT DISCUSSED AT ALL 
 
 
11. How well was it explained that Alzheimer’s tests do not tell us for certain whether a 
person will or will not develop the disease?  Would you say very well, well, not very well, or 
not well at all? 
1 VERY WELL 
2 WELL 
3 NOT VERY WELL 
4 NOT WELL AT ALL 
5 WAS NOT DISCUSSED AT ALL  (SKIP TO 12) 
 
 
11a. As best as you can remember, based on the explanation you received, what does a 




1 WAS NOT DISCUSSED 






12. How well was it explained that the results from a test for Alzheimer’s Disease might 
affect your ability to get health insurance in the future? 
1 VERY WELL 
2  WELL 
3 NOT VERY WELL 
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4 NOT WELL AT ALL 
5 WAS NOT DISCUSSED AT ALL 
 
13. How helpful was the discussion you had for understanding how taking the test might 
affect your family?  Would you say very helpful, moderately helpful, not very helpful, or not 
helpful at all? 
1 VERY HELPFUL 
2  MODERATELY HELPFUL 
3 NOT VERY HELPFUL 
4 NOT HELPFUL AT ALL 
5  NOT COVERED BY THE GENETIC COUNSELING 
 
13a.  Did the person explaining the test tell you whether or not your blood sample could be 
used for future research? 
1 YES  
2 NO  
3 DON’T RECALL 
 
14. Were you allowed to have the results of your test for Alzheimer’s? 
1 YES  (SKIP TO 16) 
  2 NO 
 
15. How strong was your desire to know the results of your genetic test for Alzheimer’s 
Disease, would you say it was very strong, moderately strong, not very strong, or not strong at 
all? 
1 VERY STRONG  (SKIP TO 17) 
2 MODERATELY STRONG  (SKIP TO 17) 
3 NOT VERY STRONG 
4 NOT STRONG AT ALL 
5 DON’T KNOW  (SKIP TO 17) 
 
15a. Why weren’t you interested in the results? 
 __________________________________________ 
 __________________________________________ 
 __________________________________________ (SKIP TO 17) 
 
16. Can you recall the specific results of your genetic test for Alzheimer’s Disease? 
1 YES 
2 NO   (SKIP TO 17) 
2 NEVER GOT RESULTS   (SKIP TO 17) 
 
16a. What were the results of your test? 
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1 HOMOZYGOUS E2/E2 
2 HETEROZYGOUS E2/E3 
3 HETEROZYGOUS E2/E4 
4 HOMOZYGOUS E3/E3  
5  HETEROZYGOUS E3/E4 
6 HOMOZYGOUS E4/E4 
7 SOMETHING ELSE (SPECIFY_______________________________) 
9  DONT KNOW  (SKIP TO 17) 
 
16b. Does this result indicate you have an increased chance of getting Alzheimer’s Disease? 
1 YES 
2 NO 
9 DON’T KNOW 
 
 
17. On a 0 to 10 scale where 0 is no certainty at all and 10 is complete certainty, how certain 
are you that your test results will be kept confidential? 
 
NO CERTAINTY AT ALL    COMPLETE CERTAINTY 
0 1 2 3 4 5 6 7 8 9 10 
 
ABSTRACT CHOICES - PHYSICAL SAMPLES 
 
1. Now I want you to help with another research problem.  Suppose you had participated in 
a research study on Alzheimer's Disease two years ago and as part of that study the 
researcher took a sample of your blood.  Now the researcher would like to do more 
research with your blood sample. 
 
Should the researcher have to get permission from you to use the left over blood for further 
research on Alzheimer's Disease if your name is still attached to the sample? 
1 YES 
2 NO (SKIP TO 3) 
9 DON’T KNOW  (SKIP TO 3) 
 
 
2. What if your name and identifying information have been removed from the sample, 
should the researcher still have to get your permission a second time? 
1 YES  (SKIP TO 5) 
2 NO  (SKIP TO 4) 





3. Suppose the researcher wanted to use your blood to study a different disease, like 
diabetes, should the researcher have to get your permission to use the left over blood for that 
research if your name is still attached to the sample? 
1 YES 
2 NO (SKIP TO 5) 
9 DON’T KNOW  (SKIP TO 5) 
 
 
4. Suppose the researcher wanted to use your blood to study a disease other than 
Alzheimer’s, and your name and identifying information had been removed from the sample, 
should the researcher have to get your permission a second time? 
1 YES 
2 NO 
9 DON’T KNOW 
 
5. Imagine that while doing the new research, the researcher learned something about you, 
but wasn’t sure if it might affect your health. 
Would you want the researcher to contact you and tell you? 
1 YES 
2 NO 
9 DON’T KNOW 
 
5b. Would you want the researcher to tell your doctor? 
1 YES 
2 NO 




1. Some people have concerns about the confidentiality of information about them.  The 
confidentiality of medical records is one area of concern, while there is also concern about the 
confidentiality of credit histories and the confidentiality of employment histories, to name two 
others. 
 
Which of the 3 types of information I have mentioned, medical information, credit history 
information, or employment history information, do you think is the most likely to be misused? 

1  MEDICAL INFORMATION 
2  CREDIT HISTORY INFORMATION 
3  EMPLOYMENT HISTORY INFORMATION 




2. Which do you think is the least likely to be misused? 

1  MEDICAL INFORMATION 
2  CREDIT HISTORY INFORMATION 
3  EMPLOYMENT HISTORY INFORMATION 
4  DON’T KNOW 
 
Now I want to narrow the discussion to medical records only. 
 
3. On a 0 to 10 scale where 0 is no certainty at all and 10 is complete certainty, how certain 
are you that your medical records are kept confidential? 
 
NO CERTAINTY AT ALL    COMPLETE CERTAINTY 
0 1 2 3 4 5 6 7 8 9 10 
 
 
4. Do you think going from paper medical records to computerized medical records 
increases the risk for misuse of the information on you, decreases the risk for misuse of the 
information on you, or do you think computerization does not change the risk for misuse of the 
information on you? 

1  INCREASES THE RISK 
2  DECREASES THE RISK 
3  DOES NOT CHANGE THE RISK 





5. Has there ever been an instance when someone disclosed information about your 
medical history in a way you considered a violation of your confidentiality? 

1 YES 
2 NO  (SKIP TO H7) 
3 DONT KNOW 
 









7. Have you ever wanted to seek help for a physical or mental health problem but did not 
because you were concerned that information about you would not be kept confidential? 
      
  1 YES 
2 NO 
 
8. Several different kinds of medical information can exist on a person.  Medical 
information can include genetic information, lab test information, doctor’s notes from visits, 
and mental health information to name a few. 
 
 
For which of the 4 I mentioned genetic information, lab test information, doctor’s notes from 
visits, and mental health information, would a loss of confidentiality upset you the most? 

1  GENETIC INFORMATION 
2  LAB TEST INFORMATION 
3  DOCTOR’S NOTES FROM VISITS 
4  MENTAL HEALTH INFORMATION 
5  ALL ARE EQUALLY IMPORTANT  (SKIP TO H10) 
6  DON’T KNOW  (SKIP TO H10) 
 
 
9. Which would be second? 

1  GENETIC INFORMATION 
2  LAB TEST INFORMATION 
3  DOCTOR’S NOTES FROM VISITS 
4  MENTAL HEALTH INFORMATION 





J.  SOCIAL BACKGROUND 
 
1. What is your date of birth?  
 
 
2. Male      Female   (CIRCLE ONE, ENQUIRE IF UNSURE) 
 
3. Do you consider yourself 

1 African American 
2 Hispanic 
3 White/non-Hispanic 
4 Native American 
5 Asian 
6 Other  (PLEASE SPECIFY: __________________________) 
 
4. What is your religious background? 









5. Do you consider yourself very religious, moderately religious, not very religious, or not 
religious at all? 

1 VERY RELIGIOUS 
2 MODERATELY RELIGIOUS 
3 NOT VERY RELIGIOUS 
4 NOT RELIGIOUS AT ALL 
 
 
6. How much schooling have you had?  Would you say less than high school, high school, 
some college, completed college, some graduate school, or completed graduate school? 

1 less than high school 
2 high school 
3 some college 
4 completed college 
5 some graduate school 
107 
 
6 completed graduate school 
 
7. Are you currently: 

1 Employed full-time 
2 Employed part-time 
3 Not employed 
4 Retired 
5 SOMETHING ELSE (PLEASE SPECIFY) ____________________ 
 
 
8. Approximately how much did you and your immediate family earn last year before 
taxes? 






6 Over  $100,000 
7 REFUSED 
9 DON’T KNOW 
 
 
9. How would you rate your personal health, would you say it is excellent, very good, 
good, fair, or poor? 

1 EXCELLENT 
2 VERY GOOD 





10. Have you been hospitalized: 
 















Coming to the end, I would like to know what it was like for you to answer my questions 
 
1. First, how much stress would you say that this interview caused you?  Would you say a 
great deal of stress, some stress, a little stress, or no stress at all? 
1 A GREAT DEAL OF STRESS 
2 SOME STRESS 
3 A LITTLE STRESS 
4 NO STRESS AT ALL 
 
 
2. How helpful would you say this interview was for you?  Would you say it was it was 
very helpful, moderately helpful, a little helpful, or not helpful at all? 
1 VERY HELPFUL 
2 MODERATELY HELPFUL 
3 A LITTLE HELPFUL, 
4 NOT HELPFUL AT ALL 
 
 
3. Was there anything that bothered you about the questions I asked?  
1 YES 








Those are all the questions I have.  Thank you very much for taking the time to answer my 












Title of study: Collection, storage and use of biological samples for future research: A cross-
sectional study of opinions of Pietermaritzburg government hospital out-patients. 
 
 (Acknowledgements: Survey adapted from- “The debate over research on stored biological 
samples: What do sources think?” Dave Wendler, PhD; Ezekiel Emanuel, MD, PhD) 
 
Part 1- Research/Clinical Experience 
1. Researchers have tests that allow them to detect certain diseases and assess whether they run 
in families. Have you ever had tests done using your biological material? (e.g.: blood, 
saliva, urine, stools etc…) 




1.1. Has anyone offered you a test involving your biological material that you decided not to 
have done? 
1 YES  
2 NO (SKIP TO 12) 
 




                           (SKIP TO 12) 
 
2. About how long ago were these tests run? 
1 LESS THAN 6 MONTHS AGO 
2 BETWEEN 6 MONTHS AND A YEAR AGO 
3 BETWEEN 1 AND 2 YEARS AGO 






3. Which tests were these? 





4. Did you receive an explanation or participate in a discussion about the particular test either 
before or at the time you went to receive it? 
 
 NO   (SKIP TO 7) 
 
 
5. Did you decide to be tested because you were convinced by the explanation or had you 
already decided to be tested before hearing the explanation? 
1 EXPLANATION CONVINCED 
2 ALREADY DECIDED 
3 DON’T KNOW 
 










7. Was there a discussion about the test at any time after it was performed? 
 
1 YES 
2   NO   (IF NO TO 4 AND 7, SKIP TO 12) 
 
8. Added together, how much time in minutes would you estimate was spent providing you 











9. As part of the information you received, how clearly was it explained that the test was your 
option and not a requirement? 
 
1 VERY CLEARLY 
2 CLEARLY 
3 NOT VERY CLEARLY 
4 NOT CLEARLY AT ALL 
5 WAS NOT DISCUSSED AT ALL 
 
10.  How well were the results of the test explained? 
 
1 VERY WELL 
2 WELL 
3 NOT VERY WELL 
4 NOT WELL AT ALL 
5 WAS NOT DISCUSSED AT ALL  
 
11. How helpful was the discussion you had for understanding how taking the test might affect 
your family? 
 
1 VERY HELPFUL 
2 MODERATELY HELPFUL 
3 NOT VERY HELPFUL 
4 NOT HELPFUL AT ALL 
5 NOT COVERED 
 
11.1. Did the person explaining the test tell you whether or not your biological sample 






12. On a scale of 0 to 10 (where 0 is no certainty at all and 10 is complete certainty) how certain 
are you that your test results will be kept confidential? 
 
 
NO CERTAINTY AT ALL    COMPLETE CERTAINTY 








Part 2- Consent 
 
 
1. I want you to help me with a research problem. Suppose you had surgery two years ago and 
during the operation your doctor took a sample of your tissue. Now a researcher would like 
to use that tissue in a research study 
 
 
Should the researcher have to get permission from you to use your leftover tissue for further 
research if your name is still attached to the sample? 
            1 YES 
2 NO  
3 DON’T KNOW  
 
1.1. What if your name and identifying information have been removed from the sample, 






2. Now I want you to help with another research problem.  Suppose you had participated in a 
research study on Diabetes two years ago and as part of that study the researcher took a 
sample of your blood.  Now the researcher would like to do more research with your blood 
sample. 
 
Should the researcher have to get permission from you to use the left over blood for further 
research on Diabetes if your name is still attached to the sample? 
1 YES 
2 NO  
3 DON’T KNOW  
 
 
2.1. What if your name and identifying information have been removed from the sample, should 
the researcher still have to get your permission a second time? 
1 YES  
2 NO  









3. Suppose the researcher wanted to use your blood to study a disease other than diabetes, like 
cancer; should the researcher have to get your permission to use the left over blood for that 
research if your name is still attached to the sample? 
1 YES 
2 NO (SKIP TO 5) 
3 DON’T KNOW (SKIP TO 5) 
 
 
3.1. Suppose the researcher wanted to use your blood to study a disease other than Diabetes, 
like cancer, and your name and identifying information had been removed from the sample, 
should the researcher have to get your permission a second time? 
1 YES 
2 NO 
3 DON’T KNOW 
 
*Questions 4 to 8  are based on the above scenarios is general* 
 
4. When should consent for future research be obtained? 
1 When samples are initially collected 
2 Each time a new study is proposed 
3 Other  (PLEASE SPECIFY) 






5. Who should be responsible for obtaining consent? 
1 The researcher/clinician for whom the samples were initially collected for 
2 The researcher(s) who intends to use your sample for the proposed research 
3 Other  (PLEASE SPECIFY) 
4 Don’t know 
 
6. Some researchers have proposed that individuals provide once-off general consent when 
their samples are collected so as to remove the need to re-contact sources for further 
research. Is once-off general consent enough? 
1 Yes 
2 No 
3 Other  (PLEASE SPECIFY) 







7. Should individuals be able to provide limits to the use of their samples? 
1 Yes 
2 No 
3 Other  (PLEASE SPECIFY) 
4 Don’t know 
 
 
8. Imagine that while doing the new research, the researcher learned something about you, but 
wasn’t sure if it might affect your health. 
Would you want the researcher to contact you and tell you? 
1 YES 
2 NO 
3 DON’T KNOW 
 
 
8.1. Would you want the researcher to tell your doctor? 
1 YES 
2 NO 
3 DON’T KNOW 
 
Part 3- Confidentiality 
 
1. Some people have concerns about the confidentiality of information about them.  The 
confidentiality of medical records is one area of concern, while there is also concern about the 
confidentiality of credit histories and the confidentiality of employment histories, to name two 
others. 
 
Which of the 3 types of information I have mentioned, medical information, credit history 
information, or employment history information, do you think is the most likely to be misused? 

1 MEDICAL INFORMATION 
2 CREDIT HISTORY INFORMATION 
3 EMPLOYMENT HISTORY INFORMATION 
4 DON’T KNOW 
 
2. Which do you think is the least likely to be misused? 

1 MEDICAL INFORMATION 
2 CREDIT HISTORY INFORMATION 
3 EMPLOYMENT HISTORY INFORMATION 




Now I want to narrow the discussion to medical records only. 
 
3. On a 0 to 10 scale where 0 is no certainty at all and 10 is complete certainty, how certain 
are you that your medical records are kept confidential? 
 
NO CERTAINTY AT ALL COMPLETE CERTAINTY 
0   1   2   3   4   5   6   7   8   9 10 
 
 
4. Do you think going from paper medical records to computerized medical records 
increases the risk for misuse of the information on you, decreases the risk for misuse of the 
information on you, or do you think computerization does not change the risk for misuse of the 
information on you? 

1 INCREASES THE RISK 
2 DECREASES THE RISK 
3 DOES NOT CHANGE THE RISK 





5. Has there ever been an instance when someone disclosed information about your 
medical history in a way you considered a violation of your confidentiality? 

1 YES 
2 NO (SKIP TO 7) 
3 DONT KNOW (Skip to 7) 
 







7. Have you ever wanted to seek help for a physical or mental health problem but did not 
because you were concerned that information about you would not be kept confidential? 
      






8. Several different kinds of medical information can exist on a person.  Medical 
information can include genetic information, lab test information, doctor’s notes from visits, 
and mental health information to name a few. 
 
 
For which of the 4 I mentioned genetic information, lab test information, doctor’s notes from 
visits, and mental health information, would a loss of confidentiality upset you the most? 

1 GENETIC INFORMATION 
2 LAB TEST INFORMATION 
3 DOCTOR’S NOTES FROM VISITS 
4 MENTAL HEALTH INFORMATION 
5 ALL ARE EQUALLY IMPORTANT  




9. Which would be second? 

1 GENETIC INFORMATION 
2 AB TEST INFORMATION 
3 DOCTOR’S NOTES FROM VISITS 
4 MENTAL HEALTH INFORMATION 
5 DON’T KNOW 
 
Part 4- Socio-Demographic 
 
 
1. What is your year of birth?  
 
 
2. Male      Female   (CIRCLE ONE, ENQUIRE IF UNSURE) 
 











4. What is your religious background? 






6 African Traditional Belief 





5. Do you consider yourself very religious, moderately religious, not very religious, or not 
religious at all? 

1 VERY RELIGIOUS 
2 MODERATELY RELIGIOUS 
3 NOT VERY RELIGIOUS 
4 NOT RELIGIOUS AT ALL 
 
 
6. How much schooling have you had?   

1 No schooling 
2 Primary School (grade 1 to grade 7) 
3 High School (Grade 8 to grade 12) 
4 Higher Certificate 
5 Diploma 
6 Bachelor’s Degree 
7 Post-Graduate qualification 




7. Are you currently?:  

1 Employed full-time 
2 Employed part-time 
3 Not employed 
4 Retired 





8. Approximately how much do you earn before taxes (gross income, grant, pension)? 

1 None 
2 R1 to R400 
3 R401 to R800 
4 R801 to R1600 
5 R1601 to R3200 
6 R3201 to R6400 
7 R6401 to R12800 
8 R12801 to R25600 
9 Over 25601 
                      10 REFUSED 






9. How would you rate your personal health? 

1 EXCELLENT 
2 VERY GOOD 





10. Have you been hospitalized: 
 















Part 5- Conclusion 
 
Coming to the end, I would like to know what it was like for you to answer my questions 
 
1. First, how much stress would you say that this interview caused you?  Would you say a 
great deal of stress, some stress, a little stress, or no stress at all? 
1 A GREAT DEAL OF STRESS 
2 SOME STRESS 
3 A LITTLE STRESS 
4 NO STRESS AT ALL 
 
 
2. How helpful would you say this interview was for you?  Would you say it was it was 
very helpful, moderately helpful, a little helpful, or not helpful at all? 
1 VERY HELPFUL 
2 MODERATELY HELPFUL 
3 A LITTLE HELPFUL, 
4 NOT HELPFUL AT ALL 
 
 
3. Was there anything that bothered you about the questions I asked?  
1 YES 








Those are all the questions I have.  Thank you very much for taking the time to answer my 









Appendix J: Final IsiZulu survey 
Number: …….. 
Uhlelo lwemibuzo yocwaningo 
Isihloko socwaningo: Ukuqoqwa kanye nokugcinwa kwama-sampula omzimba ukuze 
asentshenziswe kucwaningoolusesikhathini esizayo: Ucwaningo lobuningi oluhlola 
imibono yeziguli ezingalalisiwe ezibhedlela zikaHhulumeni ePietermaritzburg. 
 
(Acknowledgements: Survey adapted from- “The debate over research on stored biological 
samples: What do sources think?” Dave Wendler, PhD; Ezekiel Emanuel, MD, PhD) 
 
Ingxenye 1- Isipiliyoni socwaningo 
1. Abacwaningi banama-test abavumela ukuthi basheshe bekwazi ukubona izifo ezithile 
kumuntu futhi bebone ukuthi lezozifo ziyahamba yini emndenini. Wake wayenza i-test 
esebenzisa ama-sampula akho omzimba (isb.: igazi, amathe, umchamo, njll)? 




1.1. Ukhona owake wakucela ukuthi wenze i-test esebenzisa ama-sampula akho 
omzimba kodwa wakhetha ukungayenzi? 
1 YEBO 
2 CHA (Dlulela ku No. 12) 
 

















2. Sekudlule isikhathi esingakanani uwenzile lama-test? 
 
1 Azikakadluli izinyanga eziyisithupha 
 
2Ngaphakathi kwezinyanga eziyisithupha kuya onyakeni owodwa 
 
3 Ngaphakathi konyaka owodwa kuya kwemibili 
 
4 Ngaphezu kweminyaka emibili 
 
 
3. Imaphi lama-test? 
 





4. Wakuthola ukuchazeleka mayelana naleyo-test noma naxoxisana ngayo ngaphambi 
kokuthi uyenze noma ngenkathi uyenza? 
 
1 YEBO 
2 CHA (Dlulela ku No. 7) 
3 Angazi (Dluelela ku No. 7) 
 
5. Wathatha isinqumo sokuyenza i-test ngoba wawuchazeliwe ngayo, noma wawusuvele 
ususithathile isinqumo sokuyenza ngaphambi kokuthi uchazelwe? 
1 Ukuchwazelwa nge-test kwangenza ngithathe isinqumo sokuyenza 
 





6. Ngaphambi kokuthi uyenze i-test, kukhona okungakhulunyangwa nawe owawuthanda 
ukuthi kukhulunywe? 
1 YEBO 
2 CHA (Dlulela ku No. 7) 
 




7. Yayikhona inkulumo noma ingxoxiswano nge-test emuva kokuthi yenziwe? 
 
1 YEBO 




8. Uma usubala, ungathi kwathatha isikhathi/ imizuzu emingaki ukuze uchazelwe nge-test 
ngaphambi kokuthi uyenze, ngesikhathi uyenza kanye nangesikhathi usuyenzile? 
 
_________ Imizuzu (amaminithi) 
 
 
9. Kulolulwazi abakunika lona mayelana ne-test, bakuchazela kahle kangakanani ukuthi 
ukwenza i-test ukuzikhethela kwakho awuphoqiwe? 
 
1 Bangichazela ngokucacile kakhulu 
2 Bangichazela ngokucacile 
3 Bangichazela kancane 
4 Abangichazelanga kahle 




10. Wachazelwa kahle kangakanani ngemiphumela ye-test? 
 
1 Kahle kakhulu 
2 Kahle 
 Bangichazela kancane 
4 Abangichazelanga kahle 
5 Abangichazelanga nhlobo 
 
11. Ingxoxo yaba usizo kangakanani ekukuchazeleni ukuthi i-test ingawuthinta kanjani 
umndeni wakho? 
1 Yaba usizo kakhulu 
2 Yabo usizo olanele 
3 Ayingisizanga kakhulu 
4 Ayingisizanga nhlobo 








11.1. Umuntu owayekuchazela nge-test wakutshela ukuthi i-sampula lakho 
lomzimba lingase lisetshenziselwe olunye ucwaningo noma cha? 
 
1 YEBO 
2  CHA 
3 Angisakhumbuli 
 
12. Esikalini esisuka ku 0 siye ku 10 (la u 0 uchaze ukuthi awunaso nhlobo isiqiniseko, u 10 
uchaze ukuthi unaso isiqiniseko esiphelele) unesiqinseko esingakanani ukuthi 




      Anginaso nhlobo isiqiniseko                                         Nginesiqiniseko esiphelele 






Ingxenye 2- Imvume/ Isivumelwano 
 
 
1. Ngicela ungisize ngalesi simo esilandelayo. Akesithi ubukade uhlinziwe eminyakeni 
emibili edlule, udokotela wathatha isampula lezicubu zomuzimba wakho. Manje khona 
umcwaningi ofuna ukusebenzisa isampula lakho lezicubu zomziba kucwaningo oluthize. 
 
 
  Kumele umcwaningi athole imvume kuwena ukuze asebenzise izicubu zakho zomzimba 
ezisalile uma igama lakho lisahlangene nesampula? 
 





1.1.Uma igama lakho kanye nemininingwane ebonakalisa wena isusiwe kwisampula 










2. .Manje ngicela ungisize ngesinye isimo. Ake sithi wawukade uyingxenye yolunye 
ucwaningo Lwesifo saShukela eminyakeni emibili idlule, kulelocwaningo umcwaningi 
wathatha isampula segazi lakho. Manje lowomcwaningi usefuna ukwenza olunye 
ucwaningo ngegazi lakho. 
 
 
Kumele umcwaningi athole imvume  kuwena ukuze asebenzise igazi lakho elisalile kolunye 










2.1.  Uma igama lakho kanye nemininingwane ebonakalisa wena isusiwe kwisampula 







3. Ake sithi umcwaningi ufuna ukusebenzisa igazi lakho kucwaningo lwesinye isifo 
ekungasona esikaShukewla, njengoMdlavuza. Kungamele athole imvume yakho ukuze 




2 CHA (Dlulela ku No. 5) 
3 Angazi (Dlulela ku No. 5) 
 
 
3.1.Ake sithi umcwaninigi ufuna ukusebenzisa igazi lakho kucwaningo lwesinye isifo 
ekungasona esikashukela, njengoMdlavuza. Kungamele athola imvume yakho ukuze 
asebenzise igazi lakho uma igama lakho kanye nemininingwane ekubonakalisayo 









 *Imibuzo 4 kuya ku 9 iphathelene nalezi zimo ezingaphezulu zonke* 
 
4. Imvume yokusebenzisa amasampula akho kucwaningo lwangomuso kumele itholwe 
nini? 
 
1 Uma amasampula eqoqwa/etholwa okokuqala 
                        2 Njalo uma kuhlongozwa ucwaningo olusha 
                        3  Okunye (SICELA UCACISE) 




5. Kumele kube umsebenzi wabani ukuthole imvume? 
 
1 Umcwaningi noma abomutholampilo-okuyibona abaqoqe amasampula kuqala 
2 Umcwaningi/abacwaningi abafuna ukusebenzisa isampula lakho kucwaningo   olusha 






6. Abanye abacwaningi babona engathi kuncono ukuthi abantu banike imvume yabo 
(imvume lanoma yiluphi ucwaningo lwangomuso) kanye uma kuqoqwa amasampula 
ukuze kususe isidingo sokuthi abantu bathintwe uma kukhona ucwaningo olusha. 



















8. Ake sithi ngesikhathi umcwaningi enza ocwaningo olusha uthola okuthile ngawe 
okungase kuthinte isimo sakho sempilo 
 














Ingxenye 3- Okuyimfihlo 
 
1. Abanye abantu banokukhathazeka ngokugcineka kwemfihlo mayelana 
nemininingwane ephathelene nabo. Ukugcineka kwemfihlo kwama-rekhodi 
okulapha kuyindawo enkulu ekhathaza abantu, kanye nokugcineka kuyimfihlo 
okomlando wezimali/wokukweleta nomlando wokuqashwa. 
 
Kulezi zinhlobo ezintathu zemininingwane esengizichazile (ama-rekhodi okulapha, umlando 





1 Ama-rekhodi okulapha 
2 Umlando wezimali/wokukweleta 
3 Umlando wokuqashwa 
4 Angazi 
 
2. Yikuphi ocabanga ukuthi ngeke kwabalula ukusebenziseka ngokungeyikho? 

1 Ama-rekhodi okulapha 
2 Umlando wezimali/wokukweleta 






Manje ngisacela sigxile kwama-rekhodi okulapha kuphela 
 
3. Esikalini esisuka ku 0 siye ku 10 (la u 0 uchaze ukuthi awunaso nhlobo isiqiniseko, u 
10 uchaze ukuthi unaso isiqiniseko esiphelele) unesiqinseko esingakanani sokuthi 
amarekhodi akho okulapha agcinwa eyimfihlo? 
 
 
Anginaso nhlobo isiqiniseko                                             Nginesiqiniseko esiphelele 
0   1   2   3   4   5   6   7   8   9 10 
 
 
4. Ngokubona kwakho, ucabanga ukuthi ukusuka kwamarekhodi abhalwe ngesandla 
ephepheni kuyiwe kwamarekhodi agcinwe ekhompuyutheni kwandisa noma 
kunciphisa noma akuyishinthsi ingozi yokuthi asebenziseke ngokungeyikho? 

1 Andisa ingozi 
2 Kunciphisa ingozi 




5. Wake wabhekana nesimo lana umuntu wakhipha imininingwane yamarekhodi akho 
okulapha ngendlela obona engathi iphula okuyimfihlo kwakho? 

1 YEBO 
2 CHA (Dlulela ku No. 7) 
3 ANGAZI (Dlulela ku No. 7) 
 









7. Wake wafuna ukuthola usizo lwenkinga ephathelene ngokomzimba noma inkinga 
ephathelene ngokwengqondo kodwa wasaba ukuthi imininingwane yalezo zinkinga 
angeke igcinwe iyimfihlo? 
      




8. Kukhona izinhlobo ezihlukene zemininingwane yokwelapha zomuntu. Imininingwane 
yokwelapha kungaba ulwazi lofuzo, imiphumela yokuhlola yase-laboratory, imibhalo 
emuva kokuvakashela udokotela, kanye nemininingwane ephathelene ngokwengqondo. 
 
Kulokhu okune engikubalile (ulwazi lofuzo, imiphumela yokuhlola yase-laboratory, 
imibhalo emuva kokuvakashela udokotela, nemininingwane ephathelene ngokwenqondo) 
yikuphi okungakuphatha kabi kakhulu engase kungagcinwa ngokwemfihlo? 

1 Ulwazi lofuzo 
2 Imiphumela yokuhlola yase-laboratory 
3 Imibhalo emuva kokuvakashela udokotela 
4Imininingwane ephathelene ngokwenqondo 




9.  Yikuphi okungalandela? 


1 Ulwazi lofuzo 
2 Imiphumela yokuhlola yase-laboratory 
3 Imibhalo emuva kokuvakashela udokotela 





Ingxenye 4-Imininingwane yakho 
 
1. Unyaka wakho wokuzalwa? 
 
 
2. Owesilisa        Owesifazane   (Dweba indingiliza kokukodwa, buza uma ungenaso 
isiqiniseko) 
 




1 Umuntu Omunyama 
2 i-Khalathi 
3 i-Ndiya 
4 Umuntu Omuhlophe 
5Okunye  (SICELA UCACISE): __________________________ 
 
 
4. Ukholwa kephi? 

1 Inkolo yamaSulumane  
2 Inkolo yobuKristu 
3 Inkolo yamaKatolika 
4 Inkolo yamaJuda 
5 Inkolo yamaHindu 
6 Inkolo yeSintu yeNdabuko 
                        7) Okunye (Sicela ucacise)_______________________ 




5. Uzibona uwumuntu okholwayo kakhulu, okhalwayo ngokwanele, okholwa kancane, 
noma ongakholwi? 

1 Okholwayo kakhulu 
2 Okholwayo ngokwanele 




6. Wagcinaphi esikoleni? 

1 Angifundile 
2Isikole sebanga eliphansi (Ibanga 1 kuya kwiBanga 7) 
3) Isikole sebanga eliphezulu (Ibanga 8 kuya kwiBanga 12) 
4 Isitifiketi Esiphakeme 
5 iDiploma 
6 iBachelor’s Degree 
7 iPost-Graduate qualification 







7. Ingabe njengamanje?: 

1 Uqashwe isikhathi esigcwele 
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2 Uqashwe etohweni 
3 Awuqashiwe 
4 Usuthathe umhlalaphansi 






10.  Cishe uhola malini emva kokuthathwa kwentela (umholo, imali yokusizwa, 
impesheni) ? 

1 Angiholi/ Ayikho 
2 R1 to R400 
3 R401 to R800 
4 R801 to R1600 
5 R1601 to R3200 
6 R3201 to R6400 
7 R6401 to R12800 
8 R12801 to R25600 
9 Ngaphezu kuka 25601 






11.  Ungasikala kanjani isimo sakho sempilo? 

1 Sihle kakhulu khulu 
2 Sihle kakhulu 
3 Sihle 




10. Wake walaliswa esibhedlela: 
 












Ingxenye 5- Isiphetho 
 
Ngoba sesifika esiphethweni, ngicela ukubuza lemibuzo ephathelene nokuthi bekunjani 
ukuphendula imibuzo yami. 
 
1. Kukudalele ubunzima obungakanani ukuphendula lemibuzo?  
 
1 A Ubunzima obukhulu 
2 Ubunzima 
3 Ubunzima obuncane 
4 Bebungekho ubunzima 
 
 
2. Ungathi bekuwusizo olungakanani kuwena ukuphendula lemibuzo? 
 
1 Bekuwusizo olukhulu 
2 Bekuwusizo ngokwanele 
3 Bekuwusizo kancane 
4 Bekungelona usizo 
 
 













Iyona yonke imibuzo ebengithanda ukukubuza yona lena. Ngiyabonga kakhulu ngosizo 
lwakho, kanye nokuthatha isikhathi sakho ukuze uphendule imibuzo yami. Izimpendulo 
zakho zizosiza ucwaningo oluphathelene nokuqoqwa kanye nokugcinwa kwama-sampula 














Appendix K: Codebook 
 
Subject Identification 
Full variable name SPSS variable name Coding instruction 
Identification ID 0 - 150 
Hospital Hosp 1= Edendale Hoapital; 2= 
Grey’s Hospital;  
 
Part 1 Research/ Clinical Experience 
Question 
number 
Full variable name SPSS variable name  Coding instruction 
1.  Have you ever had tests done 
using HBM? 
TestHBM 1= yes; 2=no 
2.  How long ago HBM test run? LastHBMT 1= less than six 
months ago; 2= 
between 6 months 
and a year; 3= 
between 1 year and 
2 years ago; 4= 
more than 2 years 
go; 999= skipped 
3.  Received 
explanation/discussion about 
HBM test prior? 
DiscPrior 1= yes; 2= no; 3= 
don’t know; 999= 
skipped 
4.  Why did you decide to do 
HBM test? 
WhyDecd 1= explanation 
convinced; 2= 
already decided; 3= 
don’t know; 999= 
skipped 
5.  Anything not discussed prior 
to HBM test? 




5.1. What not discussed prior to 
HBM test? 
AddInfoPri 1=reason for test; 
2= living with X 
disease; 3=what 
they were going to 
do with results; 
4=no clarity 
language barrier;  
999= skipped 
6.  Discussion post HBM test? PostDisc 1= yes; 2= no; 999= 
skipped 
7.  How clear stated HBM test 
option not requirement? 
TestOpt 1= very clearly; 2= 
clearly; 3= not very 
clearly; 4= not 
clearly at all; 5= 
was not discussed at 
all; 999= skipped 
8.  How well results of HBM 
test explained? 
ResExpld 1= very well; 2= 
well; 3= not very 
well; 4= not well at 
all; 5= was not 
discussed at all; 
999= skip 
9.  Discussion of how HBM test 
might affect family helpful? 
TestFam 1= very helpful; 2= 
moderately helpful; 
3= not very helpful; 
4= not helpful at all; 
5= not covered; 
999= skipped 
9.1. Possibility of future research 
with HBM discussed? 
FutRes 1= yes; 2= no; 3= 
don’t recall; 999= 
skipped 
10.  Scale of certainty of ConfdRes 0 – 10: 0= no 
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confidentiality of HBM test 
results 
certainty at all; 10= 
complete certainty 
 
Part 2- Consent 
Question 
number 
Full variable name SPSS variable name Coding Instruction 
1.  Consent for residual 
identifiable clinical sample 
necessary? 
ClinID 1= yes; 2= no; 3= 
don’t know 
1.1. Consent for residual 
unidentifiable clinical sample 
necessary? 
ClinUD 1= yes; 2= no; 3= 
don’t know 
2.  Consent for residual 
identifiable research sample 
necessary? 
RschID 1= yes; 2= no; 3= 
don’t know 
2.1. Consent for residual 
unidentifiable research sample 
necessary? 
RschUD 1= yes; 2= no; 3= 
don’t know 
3.  Consent for different disease 
research on residual 
identifiable sample necessary? 
RschDiffID 1= yes; 2= no; 3= 
don’t know 
3.1. Consent for different disease 
research on residual 
identifiable sample necessary? 
RschDiffUD 1= yes; 2= no; 3= 
don’t know 
4.  When to obtain consent for 
future research? 
WhenCons 1= when samples are 
initially collected; 2= 
each time a new 
study is proposed; 
qualitative responses; 
4= don’t know 
5.  Who should obtain consent? WhoCons 1= the researcher or 




for; 2= the researcher 
who intends to use 
your samples for 
proposed research; 
3= Doctor or  nurse; 
4= don’t know 
5=LAB 
6.  Is onetime general consent 
sufficient? 
OTGenCons 1= yes; 2= no; other 
qualitative responses 
4= don’t know 
7.  Should individuals be able to 
provide limits to use of 
samples 
Limits 1= yes; 2= no; other 
qualitative responses 
4= don’t know 
8.  Desirability of clinically 
significant results 
ClinSigRes 1= yes; 2= no; 3= 
don’t know 
8.1. Desirability to inform doctor 
of clinically significant results  




Part 3- Confidentiality 
Question 
number 
Full variable name  SPSS variable name Coding instruction 
1.  Confidential  information most 
likely to be misused 









2.  Confidential information least 
likely to be misused 





information; 4= don’t 
know 
3.  Scale of certainty of medical 
records being kept confidential 
ConfdMR 0 – 10: 0= no 
certainty at all; 10= 
complete certainty 
4.  Risk of moving from paper to 
computerized records change 
MRPprCom 1= increases the risk; 
2= decreases the risk; 
3= does not change 
the risk; 4= don’t 
know 
5.  Has confidentiality of your 
medical record ever been 
violated 
ConfdViol 1= yes; 2= no; 3= 
don’t know 
6.  Circumstances confidentiality 
medical record violated 
CircmViol 1= assurance not 
given; 2= nurses 
disclosed; 3= dr 
disclosed pregnancy 
to parents; 4= space 
was not private  
999= skip 
7.  Avoided seeking psychical or 
mental help out of concerns of 
confidentiality 
FearConfd 1= yes; 2= no 
8.  Medical information most 
sensitive 
InfoSens 1= genetic 
information; 2= lab 
test information; 3= 
doctors notes from 




5= all are equally 
important; 6= don’t 
know 
9.  Medical information second 
most sensitive 
Info2Sens 1= genetic 
information; 2= lab 
test information; 3= 
doctors notes from 
visits; 4= mental 
health information; 
5= don’t know 
 
Part – Sociodemographic Information 
Question 
number 
Full variable name SPSS variable name Coding instruction 
1.  Age  Age Numerical age 
grouping 
2.  Sex  Sex  1= male; 2= female 
3.  Race Race 1= African/Black; 2= 
Coloured; 3= 
Indian/Asian; 4= 
White; 5= other 
4.  Religion Religion 1= Muslim; 2= 
Christian; 3= 
Catholic; 4= Jewish; 
5= Hindu; 6= African 
Traditional Belief; 
7=; Apostolic 
Church; 8= None 




3= not very religious; 
4= not religious at all 
6.  Level of Education Education 1= No schooling; 2= 
Primary School 
(grade 1 to grade 7); 
3= High School 
(Grade 8 to grade 
12); 4= Higher 
Certificate; 5= 
Diploma; 6= 




7.  Current employment Employment 1= employed full 
time; 2= employed 
part time; 3= not 
employed; 4= retired; 
5= student; 6= self 
employed 
8.  Income before taxes Income 1= None; 2=  R1 to 
R400; 3= R401 to 
R800; 4= R801 to 
R1600; 5= R1601 to 
R3200; 6= R3201 to 
R6400; 7= R6401 to 
R12800; 8= R12801 
to R25600; 9= Over 
25600; 10=Refused; 






9.  Rate personal health Health 1= excellent; 2= very 
good; 3= good; 4= 
fair; 5= poor 
10.1.  Hospitalisation in past year Hospital1 1= yes; 2= no 
10.2.  Hospitalisation past 5 years Hospital5 1= yes; 2= no 
 
Part 5= Conclusion 
Question 
Number 
Full variable name SPSS name Coding instruction 
1.  Stressed caused by survey Stress 1= a great deal of 
stress; 2= some 
stress; 3= a little 
stress; 4= no stress 
at all 
2.  How helpful was survey Helpful 1= very helpful; 2= 
moderately helpful; 
3= a little helpful; 
4= not helpful at all 
3.  Anything that bothered you 
about survey 
Bother 1= yes; 2= no 
3.1. What bothered you WhatBother 1= salary question; 
2= everything; 3= 
did not understand 
the point; 4= 


























How long ago were these HBM test run? 
less than six months ago 
between 6 months and a year 
between 1 year and 2 years 
more than 2 years ago 











































Anything not discussed prior to HBM test 
Yes 
No  









What not discussed prior to HBM test 
reason for test 
living with X illness/disease 
what they were going to do with results 
no clarity- language barrier 













Discussion post HBM test 
Yes 
No 









How well results of HBM test explained 
very well 
well 
not very well 
not well at all 













How clearly stated HBM test is an option 
very clear 
clearly 
not very clearly 
not clearly at all 
was not discussed at all 















Discussion of how HBM test might affect family 
very well 
well 
not very well 













was not discussed at all 





















Table 3. Frequency table of consent for research on stored human biological samples 
Question Overall frequency 
(N=200) 
Percentage (%) 








































































When to obtain consent for future research 
When samples initially collected 














Who should obtain consent 
Researcher/clinician samples initially collected for 
Researcher who intends to use samples 






















































Table 4. Frequency table of desirability of clinically significant results 





































Confidential information most likely to be misused 
medical information 
credit history information 












Confidential information least likely to be misused 
medical information 
credit history information 












Risk of moving from paper to computerized records change 
increases the risk 
decreases the risk 



































Medical info most sensitive 
genetic information 
lab test information 
doctors notes from visits 
mental health informatiom 




















Figure 1-  Consent for residual identifiable clinical samples * current 
employment 
 
(a) Chi-Square Tests 
 





 10    .018 
Likelihood Ratio 24.886 10   .006 
Linear-by-Linear 
Association 
.338 1 .561 
N of Valid Cases 200   
 
a. 8 cells (44,4%) have expected count less than 5. The minimum expected count is ,18. 
 
 






Nominal by Nominal 
Phi .327 .018 
Cramer's V .232 .018 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 












Figure 2- Consent for residual identifiable clinical samples * income before taxes 
 
(a) Chi-Square Tests 
 





 20 .014 
Likelihood Ratio 33.957 20 .026 
Linear-by-Linear 
Association 
.708 1 .400 
N of Valid Cases 200   
a. 21 cells (63,6%) have expected count less than 5. 








Nominal by Nominal 
Phi .427 .014 
Cramer's V .302 .014 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 




Figure 3 - Consent for residual identifiable clinical sample * hospital 
 
(a) Chi-Square Tests 
 




 2 .005 
Likelihood Ratio 11.902 2 .003 
Linear-by-Linear 
Association 
4.976 1 .026 
N of Valid Cases 200   
a. 0 cells (,0%) have expected count less than 5. The 
minimum expected count is 8,46. 
 
 
(b) Symmetric Measures 
 
 Value Approx. Sig. 
Nominal by Nominal 
Phi .228 .005 
Cramer's V .228 .005 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 












Figure 4 - Consent for residual unidentifiable clinical samples* current employment 
 
(a) Chi-Square Tests 
 








 10 .070 
Likelihood Ratio 20.058 10 .029 
Linear-by-Linear 
Association 
.195 1 .658 
N of Valid Cases 200   
a. 9 cells (50,0%) have expected count less than 5. 
The minimum expected count is ,18. 
 
 





Nominal by Nominal 
Phi .293 .070 
Cramer's V .207 .070 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 





Figure 5 - Consent for residual unidentifiable clinical samples * income before taxes 
 
(a) Chi-Square Tests 
 







 20 .071 
Likelihood Ratio 34.102 20 .025 
Linear-by-Linear 
Association 
.689 1 .407 
N of Valid Cases 200   
a. 19 cells (57,6%) have expected count less than 5. 
The minimum expected count is ,09. 
 
 





Nominal by Nominal 
Phi .387 .071 
Cramer's V .274 .071 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 












(a) Chi-Square Tests 
 




 6 .034 
Likelihood Ratio 13.970 6 .030 
Linear-by-Linear 
Association 
3.965 1 .046 
N of Valid Cases 172   
a. 4 cells (33,3%) have expected count less than 5. The minimum 
expected count is 2,27. 
 
 
(b) Symmetric Measures 
 
 Value Approx. Sig. 
Nominal by Nominal 
Phi .282 .034 
Cramer's V .199 .034 
N of Valid Cases 172  
a. Not assuming the null hypothesis. 




Figure 7- Consent for residual unidentifiable clinical sample * Discussion post HBM 
test 
 
(a) Chi-Square Tests 
 




 2 .048 
Likelihood Ratio 6.245 2 .044 
Linear-by-Linear 
Association 
1.140 1 .286 
N of Valid Cases 172   
a. 1 cells (16,7%) have expected count less than 5. 




(b) Symmetric Measures 
 
 Value Approx. Sig. 
Nominal by Nominal 
Phi .188 .048 
Cramer's V .188 .048 
N of Valid Cases 172  
a. Not assuming the null hypothesis. 










Figure 8- Consent for residual identifiable research sample * hospital 
 
(a) Chi-Square Tests 
 




 2 .019 
Likelihood Ratio 8.336 2 .015 
Linear-by-Linear 
Association 
.627 1 .429 
N of Valid Cases 200   
a. 0 cells (,0%) have expected count less than 5. 




(b) Symmetric Measures 
 








N of Valid Cases 200  
a. Not assuming the null hypothesis. 





Figure 9- Consent for residual unidentifiable research sample* hospital 
 
(a) Chi-Square Test 
 






 2 .040 
Likelihood Ratio 6.772 2 .034 
Linear-by-Linear 
Association 
1.248 1 .264 
N of Valid Cases 200   
a. 0 cells (,0%) have expected count less than 








(b) Symmetric Measures 
 
 Value Approx. Sig. 
Nominal by Nominal 
Phi .179 .040 
Cramer's V .179 .040 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 






Figure 10- Consent for residual unidentifiable research samples * Discussion post 
HBM test 
 
(a) Chi-Square Tests 
 




 2 .023 
Likelihood Ratio 7.868 2 .020 
Linear-by-Linear 
Association 
.479 1 .489 
N of Valid Cases 172   
a. 1 cells (16,7%) have expected count less than 




(b) Symmetric Measures 
 
 Value Approx. Sig. 
Nominal by Nominal 
Phi .209 .023 
Cramer's V .209 .023 
N of Valid Cases 172  
a. Not assuming the null hypothesis. 




Figure 11- Consent for research studying a disease other than what the sample was 
initially collected for  using unidentifiable human biological samples* personal health 
 
(a) Chi-Square Tests 
 







 8 .043 
Likelihood Ratio 15.693 8 .047 
Linear-by-Linear 
Association 
5.029 1 .025 
N of Valid Cases 200   
a. 2 cells (13,3%) have expected count less than 
5. The minimum expected count is 2,09. 
 
 





Nominal by Nominal 
Phi .282 .043 
Cramer's V .200 .043 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 









Figure 12- Consent for research studying a disease other than what the sample was 
initially collected for  using unidentifiable human biological samples * hospital 
 
(a) Chi-Square Tests 
 






 2 .003 
Likelihood Ratio 13.046 2 .001 
Linear-by-Linear 
Association 
8.326 1 .004 
N of Valid Cases 200   
a. 0 cells (,0%) have expected count less than 5. 
The minimum expected count is 10,34. 
 
 
(b) Symmetric Measures 
 
 Value Approx. Sig. 
Nominal by Nominal 
Phi .242 .003 
Cramer's V .242 .003 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 




Figure 13- Consent for research studying a disease other than what the sample was 
initially collected for  using unidentifiable human biological samples * How long ago 
last HBM test 
 
(a) Chi-Square Tests 
 






 6 .031 
Likelihood Ratio 13.712 6 .033 
Linear-by-Linear 
Association 
2.654 1 .103 
N of Valid Cases 172   
a. 2 cells (16,7%) have expected count less than 
5. The minimum expected count is 2,87. 
 
 
(b) Symmetric Measures 
 
 Value Approx. Sig. 
Nominal by Nominal 
Phi .284 .031 
Cramer's V .201 .031 
N of Valid Cases 172  
a. Not assuming the null hypothesis. 











Figure 14- When should consent be obtained * personal health 
 
(a) Chi-Square Tests 
 







 12 .001 
Likelihood Ratio 34.418 12 .001 
Linear-by-Linear 
Association 
1.238 1 .266 
N of Valid 
Cases 
200   
a. 8 cells (40,0%) have expected count less than 
5. The minimum expected count is ,86. 
 
 





Nominal by Nominal 
Phi .415 .001 
Cramer's V .240 .001 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 




Figure 15- When should consent be obtained * hospital 
 
(a) Chi-Square Tests 
 






 3 .002 
Likelihood Ratio 15.113 3 .002 
Linear-by-Linear 
Association 
13.799 1 .000 
N of Valid Cases 200   
a. 2 cells (25,0%) have expected count less than 







(b) Symmetric Measures 
 
 Value Approx. 
Sig. 
Nominal by Nominal 
Phi .270 .002 
Cramer's V .270 .002 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 









Figure 16- Should individuals be able to provide limits to the use of their samples * 
religious 
 
(a) Chi-Square Tests 
 







 21 .073 
Likelihood Ratio 35.254 21 .026 
Linear-by-Linear 
Association 
10.427 1 .001 
N of Valid 
Cases 
200   
a. 21 cells (65,6%) have expected count less than 
5. The minimum expected count is ,06. 
 
 




Nominal by Nominal 
Phi .394 .073 
Cramer's V .227 .073 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 




Figure 17- Should individuals be able to provide limits to the use of their samples * 
How religious 
 
(a) Chi-Square Tests 
 






 9 .000 
Likelihood Ratio 28.978 9 .001 
Linear-by-Linear 
Association 
11.043 1 .001 
N of Valid Cases 200 
  
a. 4 cells (25,0%) have expected count less than 5. The 
minimum expected count is ,90. 
 
 





Nominal by Nominal 
Phi .386 .000 
Cramer's V .223 .000 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 






Figure 18- Desirability of clinically significant results * discussion post HBM test 
 
(a) Chi-Square Tests 
 




 2 .106 
Likelihood Ratio 7.502 2 .023 
Linear-by-Linear 
Association 
2.219 1 .136 
N of Valid Cases 172   
a. 3 cells (50,0%) have expected count less than 
5. The minimum expected count is 1,19. 
 
 
(b) Symmetric Measures 
 








N of Valid Cases 172  
a. Not assuming the null hypothesis. 







Figure 19- Desirability to inform doctor of clinically significant results * sex 
 
(a) Chi-Square Tests 
 







 2 .025 
Likelihood Ratio 7.167 2 .028 
Linear-by-Linear 
Association 
2.474 1 .116 
N of Valid Cases 200   
a. 1 cells (16,7%) have expected count less than 
5. The minimum expected count is 4,81. 
 
 





Nominal by Nominal 
Phi .192 .025 
Cramer's V .192 .025 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 






Figure 20- Desirability to inform doctor of clinically significant results * level of 
education 
 
(a) Chi-Square Tests 
 







 12 .017 
Likelihood Ratio 21.371 12 .045 
Linear-by-Linear 
Association 
4.562 1 .033 
N of Valid 
Cases 
200   
a. 12 cells (57,1%) have expected count less than 
5. The minimum expected count is ,33. 
 
 





Nominal by Nominal 
Phi .350 .017 
Cramer's V .248 .017 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 







Figure 21- Desirability to inform doctor of clinically significant results * rate personal 
health 
 
(a) Chi-Square Tests 
 







 8 .020 
Likelihood Ratio 21.090 8 .007 
Linear-by-Linear 
Association 
.009 1 .924 
N of Valid Cases 200   
a. 7 cells (46,7%) have expected count less than 
5. The minimum expected count is 1,24. 
 
 








Phi .301 .020 
Cramer's V .213 .020 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 




Figure 22- Desirability to inform doctor of clinically significant results * have you ever 
had tests run using your human biological samples 
 
(a) Chi-Square Tests 
 




 2 .027 
Likelihood Ratio 6.421 2 .040 
Linear-by-Linear 
Association 
6.895 1 .009 
N of Valid Cases 200   
a. 2 cells (33,3%) have expected count less than 
5. The minimum expected count is 1,76. 
 
 
(b) Symmetric Measures 
 
 Value Approx. Sig. 
Nominal by Nominal 
Phi .190 .027 
Cramer's V .190 .027 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 







Figure 23- Confidential information most likely to be misused * religion 
 
(a) Chi-Square Tests 
 







 21 .079 
Likelihood Ratio 33.912 21 .037 
Linear-by-Linear 
Association 
6.053 1 .014 
N of Valid 
Cases 
200   
a. 21 cells (65,6%) have expected count less than 
5. The minimum expected count is ,15. 
 
 





Nominal by Nominal 
Phi .392 .079 
Cramer's V .226 .079 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 







Figure 24- Confidential information most likely to be misused * hospital 
 
(a) Chi-Square Tests 
 






 3 .000 
Likelihood Ratio 23.763 3 .000 
Linear-by-Linear 
Association 
22.035 1 .000 
N of Valid Cases 200   
a. 0 cells (,0%) have expected count less than 5. 
The minimum expected count is 7,05. 
 
 
(b) Symmetric Measures 
 
 Value Approx. Sig. 
Nominal by Nominal 
Phi .339 .000 
Cramer's V .339 .000 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 




Figure 25- Confidential information least likely to be misused * hospital 
 
(a) Chi-Square Tests 
 





 3 .025 
Likelihood 
Ratio 




3.196 1 .074 




a. 0 cells (,0%) have expected count less than 5. The 











(b) Symmetric Measures 
 
 Value Approx. Sig. 
Nominal by Nominal 
Phi .217 .025 
Cramer's V .217 .025 
N of Valid Cases 200  
a. Not assuming the null hypothesis. 
b. Using the asymptotic standard error assuming the null 
hypothesis. 
1 
 
 
 
 
 
 
 
 
